<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Anti‐vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity - Sankar, MJ - 2018 | Cochrane Library</title> <meta content="Anti‐vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity - Sankar, MJ - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009734.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Anti‐vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity - Sankar, MJ - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009734.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009734.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Anti‐vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity" name="citation_title"/> <meta content="Mari Jeeva Sankar" name="citation_author"/> <meta content="All India Institute of Medical Sciences" name="citation_author_institution"/> <meta content="jeevasankar@gmail.com" name="citation_author_email"/> <meta content="Jhuma Sankar" name="citation_author"/> <meta content="All India Institute of Medical Sciences" name="citation_author_institution"/> <meta content="Parijat Chandra" name="citation_author"/> <meta content="Dr. R. P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences (AIIMS)" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD009734.pub3" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/01/08" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009734.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009734.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009734.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Angiogenesis Inhibitors [*administration &amp; dosage, adverse effects]; Aptamers, Nucleotide [*administration &amp; dosage, adverse effects]; Bevacizumab [*administration &amp; dosage, adverse effects]; Combined Modality Therapy; Cryotherapy [methods]; Intravitreal Injections; Laser Therapy [methods]; Randomized Controlled Trials as Topic; Ranibizumab [*administration &amp; dosage, adverse effects]; Retinal Detachment [prevention &amp; control]; Retinopathy of Prematurity [*drug therapy]; Vascular Endothelial Growth Factor A [*antagonists &amp; inhibitors]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009734.pub3&amp;doi=10.1002/14651858.CD009734.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009734.pub3&amp;doi=10.1002/14651858.CD009734.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009734.pub3&amp;doi=10.1002/14651858.CD009734.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009734.pub3&amp;doi=10.1002/14651858.CD009734.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009734.pub3&amp;doi=10.1002/14651858.CD009734.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009734.pub3&amp;doi=10.1002/14651858.CD009734.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009734.pub3&amp;doi=10.1002/14651858.CD009734.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009734.pub3&amp;doi=10.1002/14651858.CD009734.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009734.pub3&amp;doi=10.1002/14651858.CD009734.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009734.pub3&amp;doi=10.1002/14651858.CD009734.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009734.pub3&amp;doi=10.1002/14651858.CD009734.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009734.pub3&amp;doi=10.1002/14651858.CD009734.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009734.pub3&amp;doi=10.1002/14651858.CD009734.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009734.pub3&amp;doi=10.1002/14651858.CD009734.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009734.pub3&amp;doi=10.1002/14651858.CD009734.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009734.pub3&amp;doi=10.1002/14651858.CD009734.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009734.pub3&amp;doi=10.1002/14651858.CD009734.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009734.pub3&amp;doi=10.1002/14651858.CD009734.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009734.pub3&amp;doi=10.1002/14651858.CD009734.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009734.pub3&amp;doi=10.1002/14651858.CD009734.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009734.pub3&amp;doi=10.1002/14651858.CD009734.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009734.pub3&amp;doi=10.1002/14651858.CD009734.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009734.pub3&amp;doi=10.1002/14651858.CD009734.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="7a2tKMcJ";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009734\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009734\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009734\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009734\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","ms","zh_HANS","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009734.pub3",title:"Anti\\u2010vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity",firstPublishedDate:"Jan 8, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neonatal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7a2tKMcJ&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009734.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009734.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009734.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009734.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009734.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009734.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009734.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009734.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009734.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009734.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7258 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009734.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009734.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009734.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009734.pub3/full#CD009734-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009734.pub3/full#CD009734-sec-0106"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009734.pub3/full#CD009734-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009734.pub3/full#CD009734-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009734.pub3/full#CD009734-sec-0027"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009734.pub3/full#CD009734-sec-0028"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009734.pub3/full#CD009734-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009734.pub3/full#CD009734-sec-0100"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009734.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009734.pub3/appendices#CD009734-sec-0111"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009734.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009734.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/table_n/CD009734StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/table_n/CD009734StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009734.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009734.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009734.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009734.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009734.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009734.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Anti‐vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009734.pub3/information#CD009734-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Mari Jeeva Sankar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009734.pub3/information#CD009734-cr-0003">Jhuma Sankar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009734.pub3/information#CD009734-cr-0004">Parijat Chandra</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/information/en#CD009734-sec-0122">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 08 January 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009734.pub3">https://doi.org/10.1002/14651858.CD009734.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009734-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009734-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009734-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009734-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009734-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009734-abs-0001" lang="en"> <section id="CD009734-sec-0001"> <h3 class="title" id="CD009734-sec-0001">Background</h3> <p>Vascular endothelial growth factor (VEGF) plays a key role in angiogenesis in foetal life. Researchers have recently attempted to use anti‐VEGF agents for the treatment of retinopathy of prematurity (ROP), a vasoproliferative disorder. The safety and efficacy of these agents in preterm infants with ROP is currently uncertain. </p> </section> <section id="CD009734-sec-0002"> <h3 class="title" id="CD009734-sec-0002">Objectives</h3> <p>To evaluate the efficacy and safety of anti‐VEGF drugs when used either as monotherapy, that is without concomitant cryotherapy or laser therapy, or in combination with planned cryo/laser therapy in preterm infants with type 1 ROP (defined as zone I any stage with plus disease, zone I stage 3 with or without plus disease, or zone II stage 2 or 3 with plus disease). </p> </section> <section id="CD009734-sec-0003"> <h3 class="title" id="CD009734-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2016, Issue 11), MEDLINE (1966 to 11 December 2016), Embase (1980 to 11 December 2016), CINAHL (1982 to 11 December 2016), and conference proceedings. </p> </section> <section id="CD009734-sec-0004"> <h3 class="title" id="CD009734-sec-0004">Selection criteria</h3> <p>Randomised or quasi‐randomised controlled trials that evaluated the efficacy or safety of administration, or both, of anti‐VEGF agents compared with conventional therapy in preterm infants with ROP. </p> </section> <section id="CD009734-sec-0005"> <h3 class="title" id="CD009734-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane and Cochrane Neonatal methods for data collection and analysis. We used the GRADE approach to assess the quality of the evidence. </p> </section> <section id="CD009734-sec-0006"> <h3 class="title" id="CD009734-sec-0006">Main results</h3> <p>Six trials involving a total of 383 infants fulfilled the inclusion criteria. Five trials compared intravitreal bevacizumab (n = 4) or ranibizumab (n = 1) with conventional laser therapy (monotherapy), while the sixth study compared intravitreal pegaptanib plus conventional laser therapy with laser/cryotherapy (combination therapy). </p> <p>When used as monotherapy, bevacizumab/ranibizumab did not reduce the risk of complete or partial retinal detachment (3 studies; 272 infants; risk ratio (RR) 1.04, 95% confidence interval (CI) 0.21 to 5.13; risk difference (RD) 0.00, 95% CI ‐0.04 to 0.04; very low‐quality evidence), mortality before discharge (2 studies; 229 infants; RR 1.50, 95% CI 0.26 to 8.75), corneal opacity requiring corneal transplant (1 study; 286 eyes; RR 0.34, 95% CI 0.01 to 8.26), or lens opacity requiring cataract removal (3 studies; 544 eyes; RR 0.15, 95% CI 0.01 to 2.79). The risk of recurrence of ROP requiring retreatment also did not differ between groups (2 studies; 193 infants; RR 0.88, 95% CI 0.47 to 1.63; RD ‐0.02, 95% CI ‐0.12 to 0.07; very low‐quality evidence). Subgroup analysis showed a significant reduction in the risk of recurrence in infants with zone I ROP (RR 0.15, 95% CI 0.04 to 0.62), but an increased risk of recurrence in infants with zone II ROP (RR 2.53, 95% CI 1.01 to 6.32). Pooled analysis of studies that reported eye‐level outcomes also revealed significant increase in the risk of recurrence of ROP in the eyes that received bevacizumab (RR 5.36, 95% CI 1.22 to 23.50; RD 0.10, 95% CI 0.03 to 0.17). Infants who received intravitreal bevacizumab had a significantly lower risk of refractive errors (very high myopia) at 30 months of age (1 study; 211 eyes; RR 0.06, 95% CI 0.02 to 0.20; RD ‐0.40, 95% CI ‐0.50 to ‐0.30; low‐quality evidence). </p> <p>When used in combination with laser therapy, intravitreal pegaptanib was found to reduce the risk of retinal detachment when compared to laser/cryotherapy alone (152 eyes; RR 0.26, 95% CI 0.12 to 0.55; RD ‐0.29, 95% CI ‐0.42 to ‐0.16; low‐quality evidence). The incidence of recurrence of ROP by 55 weeks' postmenstrual age was also lower in the pegaptanib + laser therapy group (76 infants; RR 0.29, 95% CI 0.12 to 0.7; RD ‐0.35, 95% CI ‐0.55 to ‐0.16; low‐quality evidence). There was no difference in the risk of perioperative retinal haemorrhages between the two groups (152 eyes; RR 0.62, 95% CI 0.24 to 1.56; RD ‐0.05, 95% CI ‐0.16 to 0.05; very low‐quality evidence). However, the risk of delayed systemic adverse effects with any of the three anti‐VEGF drugs is not known. </p> </section> <section id="CD009734-sec-0007"> <h3 class="title" id="CD009734-sec-0007">Authors' conclusions</h3> <p>Implications for practice: Intravitreal bevacizumab/ranibizumab, when used as monotherapy, reduces the risk of refractive errors during childhood but does not reduce the risk of retinal detachment or recurrence of ROP in infants with type 1 ROP. While the intervention might reduce the risk of recurrence of ROP in infants with zone I ROP, it can potentially result in higher risk of recurrence requiring retreatment in those with zone II ROP. Intravitreal pegaptanib, when used in conjunction with laser therapy, reduces the risk of retinal detachment as well as the recurrence of ROP in infants with type 1 ROP. However, the quality of the evidence was very low to low for most outcomes due to risk of detection bias and other biases. The effects on other critical outcomes and, more importantly, the long‐term systemic adverse effects of the drugs are not known. Insufficient data precludes strong conclusions favouring routine use of intravitreal anti‐VEGF agents ‐ either as monotherapy or in conjunction with laser therapy ‐ in preterm infants with type 1 ROP. </p> <p>Implications for research: Further studies are needed to evaluate the effect of anti‐VEGF agents on structural and functional outcomes in childhood and delayed systemic effects including adverse neurodevelopmental outcomes. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009734-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009734-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD009734-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD009734-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009734-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009734-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009734-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009734-abs-0007">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009734-abs-0002" lang="en"> <h3>Anti‐vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity </h3> <p><b>Background</b> </p> <p>Retinopathy of prematurity (ROP) is a vascular disorder of the immature retina that can result in impairment of vision and even blindness in preterm infants. It is treated primarily by ablation of the avascular retina, the removal of the part of the retina without any blood vessels by cryotherapy or laser therapy. Though these treatments result in a significant improvement in long‐term outcomes, the results are far from perfect. In addition, they cause permanent loss of the peripheral visual field. Recently, studies have been done to evaluate the use of anti‐VEGF agents to treat ROP. These agents inhibit the action of vascular endothelial growth factor (VEGF), a key regulator of new vessel formation in foetal life. Animal studies had shown significant reduction in the neovascular response following injection of anti‐VEGF antibodies into the vitreous cavity of the eyes ('intravitreal' therapy). </p> <p><b>Study characteristics</b> </p> <p>We searched scientific databases in December 2016 for studies evaluating the efficacy and safety of intravitreal therapy with anti‐VEGF agents in preterm infants with ROP. We identified six randomised controlled trials involving 383 infants. Five trials compared intravitreal bevacizumab or ranibizumab with conventional laser therapy. One trial compared intravitreal pegaptanib plus laser therapy with laser/cryotherapy alone. </p> <p><b>Key results</b> </p> <p>The results suggest that intravitreal anti‐VEGF agents reduce the risk of refractive errors (high myopia) during childhood but do not reduce the risk of retinal detachment or recurrence of ROP when used alone. Intravitreal pegaptanib used in conjunction with laser therapy reduces the risk of retinal detachment. The effects on other critical outcomes, including delayed side effects such as stroke, are not known. Further studies are needed to assess these outcomes. </p> <p><b>Quality of the evidence</b> </p> <p>We graded the quality of the evidence as very low or low for most of the key outcomes.</p> <p><b>Setting</b> </p> <p>Neonatal units in China, Czech Republic, Italy, Iran, Ireland, and USA.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009734-sec-0106" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009734-sec-0106"></div> <h3 class="title" id="CD009734-sec-0107">Implications for practice</h3> <section id="CD009734-sec-0107"> <p>Intravitreal bevacizumab/ranibizumab, when used as monotherapy, reduces the risk of refractive errors during childhood but does not reduce the risk of retinal detachment or recurrence of retinopathy of prematurity (ROP) in infants with type 1 ROP. While the intervention might reduce the risk of recurrence of ROP in infants with zone I ROP, it can potentially result in higher risk of recurrence requiring retreatment in those with zone II ROP. Intravitreal pegaptanib, when used in conjunction with laser therapy, reduces the risk of retinal detachment as well as the recurrence of ROP in infants with type 1 ROP. However, the quality of evidence was very low to low for most outcomes due to the risk of detection bias and other biases. The effects on other critical outcomes and, more importantly, the long‐term systemic adverse effects of the drugs are not known. The insufficient data precludes strong conclusions favouring routine use of intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) agents, either as monotherapy or in conjunction with laser therapy, in preterm infants with type 1 ROP. </p> </section> <h3 class="title" id="CD009734-sec-0108">Implications for research</h3> <section id="CD009734-sec-0108"> <p>Further randomised controlled trials are needed to evaluate the effect of anti‐VEGF agents, when used as monotherapy or as a part of combination therapy with laser/cryotherapy, on (i) structural and functional outcomes in childhood and (ii) delayed systemic adverse effects such as stroke, myocardial dysfunction, and adverse neurodevelopmental outcomes in preterm infants with severe ROP. The trials should ideally be large multicentre studies with adequate sample size to detect a clinically important difference in the risk of one or more of the delayed systemic adverse effects. The studies should also have adequate sample size to demonstrate benefit or harm in each of the two strata ‐ zone I and zone II ROP. An attempt should be made to ensure masking of caregivers and outcome assessors to the group allocation in these trials. Although there may be some apparently 'obvious' benefits to anti‐VEGF therapy (including simplicity of administration and cost), concerns regarding long‐term safety do not allow for more efficient trial designs such as 'non‐inferiority' studies. In addition to future trials, a registry of infants treated with any anti‐VEGF agent should be created to begin to follow the long‐term consequences of therapy in a more reliable fashion than isolated case reports. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009734-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009734-sec-0022"></div> <div class="table" id="CD009734-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Anti‐vascular endothelial growth factor therapy compared to conventional laser/cryotherapy in preterm infants with type 1 retinopathy of prematurity</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Anti‐vascular endothelial growth factor (anti‐VEGF) therapy compared to conventional laser/cryotherapy in preterm infants with type 1 retinopathy of prematurity (ROP)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> preterm infants with type 1 ROP<br/> <b>Setting:</b> neonatal units<br/> <b>Intervention:</b> anti‐VEGF therapy<br/> <b>Comparison:</b> conventional laser/cryotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with conventional laser/cryotherapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anti‐VEGF therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Structural outcome ‐ retinal detachment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.04<br/> (0.21 to 5.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>272<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/> (3 to 77) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Structural outcome ‐ complete retinal detachment</b> </p> <p>(unit of analysis: eyes)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33<br/> (0.01 to 7.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>26<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3 4 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<br/> (1 to 577) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Refractive error ‐ very high myopia ‐ at 30 months of age</b> </p> <p>(unit of analysis: eyes)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.06<br/> (0.02 to 0.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>211<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>416 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<br/> (8 to 83) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality before discharge from primary hospital</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.50<br/> (0.26 to 8.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>229<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 3 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000<br/> (5 to 158) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality at 30 months of age</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/> (0.30 to 2.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>150<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 3 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>93 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000<br/> (28 to 229) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Local adverse effects ‐ corneal opacity requiring corneal transplant</b> </p> <p>(unit of analysis: eyes)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.34<br/> (0.01 to 8.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>286<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/> (0 to 57) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Local adverse effects ‐ lens opacity requiring cataract removal</b> </p> <p>(unit of analysis: eyes)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.15<br/> (0.01 to 2.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>544<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/> (0 to 31) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of ROP (up to 6 months of age)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/> (0.47 to 1.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>193<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>204 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 per 1000<br/> (96 to 333) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of ROP</b> </p> <p>(unit of analysis: eyes)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.36<br/> (1.22 to 23.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>188<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>123 per 1000<br/> (28 to 540) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Outcome assessment not masked.<br/> <sup>2</sup>95% CI around the pooled estimate includes both 1) no effect and 2) appreciable benefit or appreciable harm.<br/> <sup>3</sup>Number of events too small.<br/> <sup>4</sup>Serious risk of bias in analysis (unit of analysis error) in one or more of the included studies.<br/> <sup>5</sup>Outcome assessment not masked, but outcome is objective.<br/> <sup>6</sup>Evidence of large heterogeneity (I<sup>2</sup> = 86%).<br/> <sup>7</sup>Unclear risk of selection bias (details of allocation concealment not provided in the individual studies). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009734-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Anti‐vascular endothelial growth factor therapy combined with laser/cryotherapy compared to laser/cryotherapy in preterm infants with type 1 retinopathy of prematurity</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Anti‐vascular endothelial growth factor (anti‐VEGF) therapy combined with laser/cryotherapy compared to laser/cryotherapy in preterm infants with type 1 retinopathy of prematurity (ROP)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> preterm infants with type 1 ROP<br/> <b>Settings:</b> neonatal units<br/> <b>Intervention:</b> anti‐VEGF combined with laser/cryotherapy<br/> <b>Comparison:</b> laser/cryotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes*</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with conventional laser/cryotherapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anti‐VEGF therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Structural outcome ‐ retinal detachment</b> </p> <p>(unit of analysis: eyes)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.26<br/> (0.12 to 0.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>152<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>393 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>102 per 1000<br/> (47 to 216) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Local adverse effects ‐ perioperative retinal haemorrhages</b> </p> <p>(unit of analysis: eyes)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.62<br/> (0.24 to 1.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>152<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1,2,3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 1000<br/> (34 to 223) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of ROP by 55 weeks' postmenstrual age</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.29<br/> (0.12 to 0.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>76<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>145 per 1000<br/> (60 to 350) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*Only the outcomes for which data are available are reported here.</p> <p><sup>#</sup>The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Outcome assessment not masked.<br/> <sup>2</sup>Serious risk of bias in analysis (unit of analysis error).<br/> <sup>3</sup>Unclear risk of selection bias<br/> <sup>4</sup>95% CI around the pooled estimate includes both 1) no effect and 2) appreciable benefit or appreciable harm. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009734-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009734-sec-0023"></div> <section id="CD009734-sec-0024"> <h3 class="title" id="CD009734-sec-0024">Description of the condition</h3> <p>Retinopathy of prematurity (ROP) is one of the major avoidable causes of childhood blindness in high‐, middle‐, and low‐income countries (<a href="./references#CD009734-bbs2-0030" title="GilbertC , MuhitM . Twenty years of childhood blindness: what have we learnt?. Community Eye Health/International Centre for Eye Health2008;21(67):46‐7. ">Gilbert 2008</a>). Essentially a neovascularising disease of the retina, ROP occurs mostly in preterm very low birth weight (VLBW) infants. With improved survival of VLBW infants, the absolute number of children with visual impairment secondary to ROP has increased in recent years (<a href="./references#CD009734-bbs2-0029" title="GilbertC , FielderA , GordilloL , QuinnG , SemigliaR , VisintinP , et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics2005;115(5):e518‐25. [PUBMED: 15805336] ">Gilbert 2005</a>; <a href="./references#CD009734-bbs2-0038" title="MantagosIS , VanderveenDK , SmithLE . Emerging treatments for retinopathy of prematurity. Seminars in Ophthalmology2009;24(2):82‐6. [PUBMED: 19373691] ">Mantagos 2009</a>). </p> <p>The incidence of ROP varies inversely with gestation and weight at birth. A multicentre study of infants born between 1986 and 1987 reported that 81.6% of infants weighing less than 1000 g developed ROP, while only 46.9% of those weighing 1000 g to 1250 g had ROP (<a href="./references#CD009734-bbs2-0042" title="PalmerEA . What have we learned about retinopathy of prematurity during the past ten years? Progress in retinopathy of prematurity. The International Symposium on Retinopathy of Prematurity; 1997; Taormina, Italy. Amsterdam/New York: Kugler Publications, 1997. ">Palmer 1997</a>). </p> <p>Other risk factors of ROP include exposure to varying oxygen concentrations, hypercapnia, anaemia, acidosis, chronic lung disease, and intraventricular haemorrhage (<a href="./references#CD009734-bbs2-0024" title="AshtonN , WardB , SerpellG . Role of oxygen in the genesis of retrolental fibroplasia; a preliminary report. British Journal of Ophthalmology1953;37(9):513‐20. [PUBMED: 13081949] ">Ashton 1953</a>; <a href="./references#CD009734-bbs2-0047" title="SmithLE . Pathogenesis of retinopathy of prematurity. Seminars in Neonatology2003;8(6):469‐73. [PUBMED: 15001119] ">Smith 2003</a>; <a href="./references#CD009734-bbs2-0049" title="TasmanW , PatzA , McNamaraJA , KaiserRS , TreseMT , SmithBT . Retinopathy of prematurity: the life of a lifetime disease. American Journal of Ophthalmology2006;141(1):167‐74. [PUBMED: 16386993] ">Tasman 2006</a>). </p> <p>The predisposition of preterm infants to the development of ROP relates to their immature retinal vasculature. In humans, retinal vascularisation begins at about 12 weeks and is completed by 36 to 40 weeks of gestation. Normally, the blood vessels develop from the optic disc and then progress outwards towards the ora serrata. Infants born before this period will, therefore, have an immature retina with a peripheral avascular zone. Retinopathy of prematurity develops if there is a disruption in the new vessel formation (angiogenesis) in this zone. The disruption of angiogenesis has been found to occur in two sequential phases: a vaso‐obliterative phase followed by a vaso‐proliferative phase (<a href="./references#CD009734-bbs2-0025" title="AshtonN , WardB , SerpellG . Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia. British Journal of Ophthalmology1954;38(7):397‐432. [PUBMED: 13172417] ">Ashton 1954</a>). In the vaso‐obliterative phase (phase 1), the normally high arterial oxygen saturation in the postnatal life coupled with hyperoxia secondary to oxygen supplementation leads to involution and loss of formed blood vessels. In the vaso‐proliferative phase (phase 2), the relatively hypoxic environment due to ischaemia caused by vessel loss coupled with the high metabolic demands of the avascular retina leads to upregulation of various angiogenic factors, resulting in abnormal neovascularisation. In most infants, the newly formed vessels regress without leaving any sequelae. However, in some infants the neovascularisation goes unchecked leading to retinal scarring, traction, and finally detachment. </p> <p>The extent and severity of ROP are traditionally described in terms of location (zones; I to III), severity (stages; 1 to 5), extent (clock hours; 1 to 12), and vascular dilatation and tortuosity (plus disease) according to the International Classification of ROP definitions (<a href="./references#CD009734-bbs2-0026" title="The Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Archives of Ophthalmology1984;102(8):1130‐4. [PUBMED: 6547831] ">Committee for Classification of ROP 1984</a>). In addition to defining the progression of the disease, this classification also serves as a guide for surgical intervention. In 2005, the classification was revised to include aggressive posterior ROP (AP‐ROP), pre‐plus disease, and a practical way to estimate the extent of zone I with the indirect ophthalmoscope. Concomitantly, the recommendations for treatment were also revised based on the results of the Early Treatment for Retinopathy of Prematurity trial (<a href="./references#CD009734-bbs2-0028" title="Early Treatment for Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy Of Prematurity randomized trial. Archives of Ophthalmology2003;121(12):1684‐94. [PUBMED: 14662586] ">ETROP Group 2003</a>). The new recommendations place more emphasis on the presence of plus disease, rather than the number of clock hours, to decide upon the need for treatment (<a href="./references#CD009734-bbs2-0022" title="Section on Ophthalmology American Academy ofPediatrics , American Academy ofOphthalmology , American Association for Pediatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics2006;117(2):572‐6. [DOI: 10.1542/peds.2005‐2749; PUBMED: 16452383] ">American Academy of Pediatrics 2006</a>). Accordingly, treatment is initiated for the following retinal ﬁndings (type 1 ROP). </p> <p> <ol id="CD009734-list-0001"> <li> <p>Zone I ROP: any stage with plus disease</p> </li> <li> <p>Zone I ROP: stage 3 ‐ no plus disease</p> </li> <li> <p>Zone II ROP: stage 2 or stage 3 with plus disease</p> </li> </ol> </p> <p>The current treatment strategy for infants with type 1 ROP involves peripheral retinal ablation by either cryotherapy or laser therapy. Both techniques result in significant improvement in the structural and functional outcomes; a Cochrane Review reported significant reduction in the risk of early unfavourable retinal structure from 47.9% to 28.1% and unfavourable visual acuity in early childhood from 63% to 50.6% following peripheral retinal ablation (<a href="./references#CD009734-bbs2-0023" title="AndersenC , PhelpsD . Peripheral retinal ablation for threshold retinopathy of prematurity in preterm infants. Cochrane Database of Systematic Reviews1999, Issue 3. [DOI: 10.1002/14651858.CD001693] ">Andersen 1999</a>). However, in a small but significant proportion of preterm infants, the disease progresses despite treatment. Also, visual fields are slightly smaller in eyes subjected to peripheral retinal ablation as compared to 'control' eyes (<a href="./references#CD009734-bbs2-0023" title="AndersenC , PhelpsD . Peripheral retinal ablation for threshold retinopathy of prematurity in preterm infants. Cochrane Database of Systematic Reviews1999, Issue 3. [DOI: 10.1002/14651858.CD001693] ">Andersen 1999</a>). Moreover, the ablation techniques are cumbersome and require sedation, general anaesthesia, or both. This has led to a quest for simpler and more effective treatment strategies. </p> </section> <section id="CD009734-sec-0025"> <h3 class="title" id="CD009734-sec-0025">Description of the intervention</h3> <p>Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis in foetal life. In the normally developing retina, VEGF is released in response to the higher oxygen demand of the retinal tissue, which leads to the development of blood vessels from the optic nerve to the periphery. In preterm infants with disrupted angiogenesis, however, the expression and levels of VEGF differ markedly in the two different phases. While the levels are suppressed in the vaso‐obliterative phase, there is an overproduction/expression of VEGF, leading to abnormal vascular proliferation in the vaso‐proliferative phase. Hugely elevated levels of VEGF have been documented in the vitreous cavity of eyes with stage 4 ROP (<a href="./references#CD009734-bbs2-0036" title="LashkariK , HiroseT , YazdanyJ , McMeelJW , KazlauskasA , RahimiN . Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. American Journal of Pathology2000;156(4):1337‐44. [PUBMED: 10751359] ">Lashkari 2000</a>). </p> <p>The key role of VEGF in inducing retinal neovascularisation prompted researchers to explore the role of anti‐VEGF drugs in the management of ROP. Intravitreal injection of neutralising anti‐VEGF antibodies had demonstrated a significant reduction in the neovascular response in animal studies (<a href="./references#CD009734-bbs2-0021" title="AielloLP , PierceEA , FoleyED , TakagiH , ChenH , RiddleL , et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF‐receptor chimeric proteins. Proceedings of the National Academy of Sciences of the United States of America1995;92(23):10457‐61. [PUBMED: 7479819] ">Aiello 1995</a>). Two anti‐VEGF drugs, namely pegaptanib sodium (a pegylated anti‐VEGF aptamer) and ranibizumab (an anti‐VEGF monoclonal antibody) had been approved by the United States Food and Drug Administration (FDA) for intraocular use in adults in neovascular and age‐related macular degeneration. The third inhibitor, bevacizumab (a humanised anti‐VEGF monoclonal antibody), is being used off‐label for intraocular injection in adults with similar results. Recently, a fourth drug ‐ Aflibercept ‐ has been approved for the treatment of wet macular degeneration in adults. The drug is a recombinant fusion protein comprising the VEGF binding portions from the extracellular domains of human VEGF receptors 1 and 2 and the Fc portion of human IgG1. Unfortunately, none of these drugs have been approved for intraocular use in children to date (<a href="./references#CD009734-bbs2-0038" title="MantagosIS , VanderveenDK , SmithLE . Emerging treatments for retinopathy of prematurity. Seminars in Ophthalmology2009;24(2):82‐6. [PUBMED: 19373691] ">Mantagos 2009</a>). However, given the limitations of existing treatment strategies (see above), many investigators have evaluated the off‐label use of these agents in infants with ROP (<a href="./references#CD009734-bbs2-0046" title="ShahPK , NarendranV , TawansyKA , RaghuramA , NarendranK . Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian Journal of Ophthalmology2007;55(1):75‐6. [PUBMED: 17189897] ">Shah 2007</a>; <a href="./references#CD009734-bbs2-0035" title="KongL , Mintz‐HittnerHA , PenlandRL , KretzerFL , Chevez‐BarriosP . Intravitreous bevacizumab as anti‐vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Archives of Ophthalmology2008;126(8):1161‐3. [PUBMED: 18695118] ">Kong 2008</a>; <a href="./references#CD009734-bbs2-0040" title="Mintz‐HittnerHA , KuffelRRJr . Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina2008;28(6):831‐8. [PUBMED: 18536599] ">Mintz‐Hittner 2008</a>). These studies ‐ predominantly case series and retrospective studies ‐ used one or more of the following approaches to evaluate the efficacy of VEGF inhibitors: </p> <p> <ol id="CD009734-list-0002"> <li> <p>monotherapy: using an anti‐VEGF drug instead of cryo/laser therapy;</p> </li> <li> <p>combination therapy: using anti‐VEGF simultaneously with cryo/laser therapy;</p> </li> <li> <p>rescue therapy: using anti‐VEGF in infants with progression of the disease despite adequate treatment and in the rare instances where the infant presents with advanced ROP (stage 4 or more). </p> </li> </ol> </p> <p>While most of the studies demonstrated the efficacy of anti‐VEGF drugs in ROP, the safety of the drugs is yet to be established. Though no significant adverse events have been reported so far, concerns still remain regarding their potential local and systemic adverse effects. By inhibiting VEGF, a key factor in regulation of angiogenesis in the developing retina as well as the central nervous system, these drugs could result in significant local and systemic adverse effects. Indeed, there have been concerns regarding the risk of cerebrovascular accidents following intravitreal ranibizumab injections in adults with age‐related macular degeneration (<a href="./references#CD009734-bbs2-0050" title="UetaT , YanagiY , TamakiY , YamaguchiT . Cerebrovascular accidents in ranibizumab. Ophthalmology2009; Vol. 116, issue 2:362. [PUBMED: 19187826] ">Ueta 2009</a>). Though bevacizumab, the most frequently tested drug in ROP, has a lower risk of systemic absorption following intravitreal injections, the distinct possibility of its systemic effects cannot be ruled out in preterm infants with immature, and often impaired, blood‐retinal barrier (<a href="./references#CD009734-bbs2-0037" title="LawJC , RecchiaFM , MorrisonDG , DonahueSP , EstesRL . Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. Journal of AAPOS2010;14(1):6‐10. [PUBMED: 20227614] ">Law 2010</a>). </p> <p>The risk of systemic absorption, though small, brings its own complexity in the methods of randomisation and analysis in trials involving a locally administered drug. For a drug with truly local action, one can randomise either the study participant or a local body part of the participant to intervention and control groups. In the former, infants would be randomised ‐ both eyes of the infants (if needed) would receive the intervention or control therapy as per the group allocation. In the latter, eyes of the infants would be randomised ‐ one eye would receive the intervention, while the other eye would receive 'control' therapy. However, if the drug is likely to have systemic effects (like most anti‐VEGF agents), randomising the body part is not an ideal method of randomisation. </p> </section> <section id="CD009734-sec-0026"> <h3 class="title" id="CD009734-sec-0026">Why it is important to do this review</h3> <p>Treatment of ROP, to date, is largely by cryotherapy or laser therapy. Although these treatments result in a significant improvement in long‐term visual outcomes, the results are far from perfect. Despite appropriate treatment, progression to tractional retinal detachment occurs in 10% to 15% of infants with high‐risk prethreshold disease (<a href="./references#CD009734-bbs2-0028" title="Early Treatment for Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy Of Prematurity randomized trial. Archives of Ophthalmology2003;121(12):1684‐94. [PUBMED: 14662586] ">ETROP Group 2003</a>). In addition, the ablation procedures invariably cause permanent loss of the peripheral visual field. Simple, effective, and less destructive treatment strategies would be preferable to these procedures. </p> <p>The recent reports of success following bevacizumab use have prompted various investigators to conduct clinical studies on the efficacy of this intervention. However, many of these studies are not powered to detect any serious adverse events ‐ local or systemic ‐ in the enrolled infants. Also, most have not systematically documented the risk of recurrence of ROP at a later age or examined the duration of follow‐up required to detect recurrence following intravitreal therapy. Given the protracted course of the disease and the short half‐life of anti‐VEGF drugs, the potential risk of recurrence is high (Wong 2015). </p> <p>An earlier systematic review on the use of bevacizumab for severe ROP that included only case reports/case series and retrospective studies found considerable variability in how bevacizumab is used for the treatment of ROP (<a href="./references#CD009734-bbs2-0039" title="MicieliJA , SurkontM , SmithAF . A systematic analysis of the off‐label use of bevacizumab for severe retinopathy of prematurity. American Journal of Ophthalmology2009;148(4):536‐43.e2. [PUBMED: 19660736] ">Micieli 2009</a>). It concluded that "further randomized control trials are warranted". The purpose of this review was to identify all available randomised controlled trials on intravitreal anti‐VEGF therapy and to systematically analyse their results. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009734-sec-0027" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009734-sec-0027"></div> <p>To evaluate the efficacy and safety of anti‐VEGF drugs when used either as monotherapy, that is without concomitant cryotherapy or laser therapy, or in combination with planned cryo/laser therapy in preterm infants with type 1 ROP (defined as zone I any stage with plus disease, zone I stage 3 with or without plus disease, or zone II stage 2 or 3 with plus disease). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009734-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009734-sec-0028"></div> <section id="CD009734-sec-0029"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009734-sec-0030"> <h4 class="title">Types of studies</h4> <p>We considered randomised or quasi‐randomised controlled trials that evaluated the efficacy or safety of administration, or both, of anti‐VEGF agents in human preterm infants for inclusion in this review. We included only those trials that used VEGF inhibitors either alone (i.e. monotherapy) or in combination with cryo/laser therapy (i.e. combination therapy). We excluded those studies that used these drugs when other treatments such as cryo/laser therapy or vitrectomy had failed ('rescue therapy'). </p> </section> <section id="CD009734-sec-0031"> <h4 class="title">Types of participants</h4> <p>We considered studies that enrolled preterm (&lt; 37 weeks' gestation at birth) infants with type 1 ROP at enrolment for inclusion. Type 1 ROP was defined as zone I any stage with plus disease, zone I stage 3 ROP with or without plus disease, or zone II stage 2 or 3 ROP with plus disease (<a href="./references#CD009734-bbs2-0028" title="Early Treatment for Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy Of Prematurity randomized trial. Archives of Ophthalmology2003;121(12):1684‐94. [PUBMED: 14662586] ">ETROP Group 2003</a>). For the purpose of this review, we excluded those studies that enrolled infants with more advanced ROP, that is stage 4 or more, at the time of enrolment (irrespective of the treatment strategy employed). </p> </section> <section id="CD009734-sec-0032"> <h4 class="title">Types of interventions</h4> <section id="CD009734-sec-0033"> <h5 class="title">Objective 1     </h5> <p> <ul id="CD009734-list-0003"> <li> <p>Intervention: administration of any anti‐VEGF agent by intravitreal route</p> </li> <li> <p>Control: cryotherapy/laser therapy</p> </li> </ul> </p> </section> <section id="CD009734-sec-0034"> <h5 class="title">Objective 2       </h5> <p> <ul id="CD009734-list-0004"> <li> <p>Intervention: intravitreal administration of VEGF inhibitors within seven days (before or after) of planned laser or cryotherapy </p> </li> <li> <p>Control: cryotherapy/laser therapy alone</p> </li> </ul> </p> </section> </section> <section id="CD009734-sec-0035"> <h4 class="title">Types of outcome measures</h4> <section id="CD009734-sec-0036"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD009734-list-0005"> <li> <p>Functional outcome: blindness or severe visual impairment (acuity ≤ 20/200) at 6 months to 12 months of corrected age. </p> </li> <li> <p>Structural outcome: progression to retinal detachment involving the macula.</p> </li> </ol> </p> </section> <section id="CD009734-sec-0037"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD009734-list-0006"> <li> <p>Functional outcome(s) at 6 months to 12 months of corrected age:</p> <ol id="CD009734-list-0007"> <li> <p>amblyopia;</p> </li> <li> <p>nystagmus; and/or</p> </li> <li> <p>refractive error in either eye.</p> </li> </ol> </li> <li> <p>Unfavourable structural outcomes, assessed at 6 months to 12 months of corrected age, and defined as: </p> <ol id="CD009734-list-0008"> <li> <p>retinal fold involving the macula;</p> </li> <li> <p>retinal detachment involving zone I of the posterior pole; and/or</p> </li> <li> <p>retrolental tissue or 'mass' obscuring the view of the posterior pole.</p> </li> </ol> </li> <li> <p>Childhood unfavourable visual acuity, assessed at four years to six years, and defined as absence of vision or Snellen visual acuity of 20/200 or worse. </p> </li> <li> <p>Mortality measured as:</p> <ol id="CD009734-list-0009"> <li> <p>death before discharge from the primary hospital;</p> </li> <li> <p>death before two years corrected age.</p> </li> </ol> </li> <li> <p>Adverse neurodevelopmental outcomes at 18 months to 24 months of corrected age:</p> <ol id="CD009734-list-0010"> <li> <p>cerebral palsy; and/or</p> </li> <li> <p>moderate to severe developmental delay as assessed on performance in formal neurodevelopmental testing such as Bayley scale. </p> </li> </ol> </li> <li> <p>Local adverse effects such as conjunctival haemorrhage, vitreous haemorrhage, and endophthalmitis after the procedure. </p> </li> <li> <p>Acute systemic effects such as apnoea requiring respiratory support and cardiorespiratory arrest during or immediately after the treatment procedure. </p> </li> <li> <p>Delayed systemic effects such as cerebrovascular accidents (stroke) and myocardial dysfunction (based on echocardiographic parameters such as ejection fraction and fractional shortening) diagnosed in the first 24 months of life. </p> </li> <li> <p>Parental satisfaction regarding the treatment procedure employed (in Likert or other such scales). </p> </li> <li> <p>Recurrence of ROP requiring retreatment up to 6 months of age.</p> </li> </ol> </p> </section> </section> </section> <section id="CD009734-sec-0038"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD009734-sec-0039"> <h4 class="title">Electronic searches</h4> <p>We used the criteria and standard methods of Cochrane and the Cochrane Neonatal Review Group (see <a href="http://neonatal.cochrane.org/resources-review-authors" target="_blank">the Cochrane Neonatal Group search strategy for specialized register</a>). We conducted a comprehensive search including: Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (Issue 11, 2016), MEDLINE (1966 to 11 December 2016) via PubMed, Embase (1980 to 11 December 2016), and CINAHL (Cumulative Index to Nursing and Allied Health Literature) (1982 to 11 December 2016) using the following search terms: (bevacizumab OR Avastin OR ranibizumab OR pegaptanib sodium OR anti‐angio* OR angiogenesis inhibitors), plus database‐specific limiters for randomised controlled trials and neonates (see <a href="./appendices#CD009734-sec-0112">Appendix 1</a> for the full search strategies for each database). We limited the searches to human studies. We did not apply any language restrictions. We searched clinical trials registries for ongoing or recently completed trials (ClinicalTrials.gov (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>), the World Health Organization International Clinical Trials Registry Platform (<a href="http://www.whoint/ictrp/search/en/" target="_blank">www.whoint/ictrp/search/en/</a>), and the ISRCTN registry (<a href="http://www.isrctn.com/" target="_blank">www.isrctn.com/</a>)). </p> </section> <section id="CD009734-sec-0040"> <h4 class="title">Searching other resources</h4> <p>We searched for unpublished studies by handsearching the conference proceedings of the Society for Pediatric Research (2002 to 2013) and American Academy of Ophthalmology Annual Meeting (1999 to 2016). We also searched the reference lists of all studies identified by the above methods. </p> </section> </section> <section id="CD009734-sec-0041"> <h3 class="title" id="CD009734-sec-0041">Data collection and analysis</h3> <section id="CD009734-sec-0042"> <h4 class="title">Selection of studies</h4> <p>For this updated review, two review authors (MJS and JS) independently searched and identified eligible trials based on the following characteristics: study population (preterm infants with type 1 ROP), study intervention (administration of anti‐VEGF drugs with or without laser/cryotherapy), and study design (randomised controlled trials). </p> <p>The review authors screened the titles and abstracts to identify potentially relevant citations. We retrieved and reviewed the full text of the article if we could not ascertain relevance by screening the title and the abstract. The review authors independently assessed the eligibility of the studies by filling out eligibility forms designed in accordance with the specified inclusion criteria. Any disagreements were resolved by discussion. </p> <p>We contacted the study investigators for additional information or for clarification of the method of randomisation, participant characteristics, details of interventions, definitions of events, additional relevant outcomes, and losses to follow‐up, as necessary. </p> </section> <section id="CD009734-sec-0043"> <h4 class="title">Data extraction and management</h4> <p>We performed data extraction using a data extraction form designed and pilot tested by the review authors. We extracted information regarding: </p> <p> <ol id="CD009734-list-0011"> <li> <p>study setting (e.g. country and settings);</p> </li> <li> <p>study intervention;</p> </li> <li> <p>sample size;</p> </li> <li> <p>length of follow‐up;</p> </li> <li> <p>randomisation procedure;</p> </li> <li> <p>risk of different biases (see <a href="#CD009734-sec-0044">Assessment of risk of bias in included studies</a>); </p> </li> <li> <p>outcomes as listed above.</p> </li> </ol> </p> <p>For dichotomous outcomes, we extracted the total number of participants for each group and the number of participants experiencing an event. For continuous outcomes, we extracted mean, standard deviation (or data required to calculate this), and the total number of participants for each group. </p> </section> <section id="CD009734-sec-0044"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (MJS and JS) independently assessed the risk of bias (low, high, or unclear) of all included trials using the Cochrane ‘Risk of bias’ tool for the following domains (<a href="./references#CD009734-bbs2-0033" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <p> <ul id="CD009734-list-0012"> <li> <p>Sequence generation (selection bias)</p> </li> <li> <p>Allocation concealment (selection bias)</p> </li> <li> <p>Blinding of participants and personnel (performance bias)</p> </li> <li> <p>Blinding of outcome assessment (detection bias)</p> </li> <li> <p>Incomplete outcome data (attrition bias)</p> </li> <li> <p>Selective reporting (reporting bias)</p> </li> <li> <p>Any other bias</p> </li> </ul> </p> <p>Any disagreements were resolved by discussion or by a third assessor. See <a href="./appendices#CD009734-sec-0113">Appendix 2</a> for a more detailed description of risk of bias for each domain.  </p> </section> <section id="CD009734-sec-0045"> <h4 class="title">Measures of treatment effect</h4> <p>We used the standard methods of the Cochrane Neonatal Review Group to synthesise the data. We expressed effects as risk ratio (RR), risk difference (RD), and 95% confidence intervals (CI) for categorical data, and mean difference (MD) and 95% CI for continuous data. For significant differences, we also calculated the number needed to treat for an additional beneficial outcome (NNTB) based on 1/RD. We used the fixed‐effect model for pooling the results of individual studies. </p> </section> <section id="CD009734-sec-0046"> <h4 class="title">Unit of analysis issues</h4> <p>We anticipated that the units of randomisation and analysis in the included trials would be individual infants and not eyes (it is difficult to randomise eyes because intravitreal anti‐VEGF can be absorbed into the systemic circulation). However, had a given study randomised eyes and not infants, we intended to use the study data but refrained from pooling these data with data of studies that had randomised infants. We decided a priori to use the eye‐level data (and not infant‐level data) in these studies, that is incidence of outcomes in eyes randomised to anti‐VEGF versus incidence of outcomes in eyes randomised to the control group; consequently, we did not consider individual‐level outcomes such as mortality or long‐term neurodevelopment in these studies. We <i>a priori</i> assumed that the beneficial effect, if any, would be diluted in these studies, that is the effect size would be closer to the null effect, if systemic absorption of anti‐VEGF agents were to occur (because the eye randomised to control group would be exposed to both anti‐VEGF agents and 'control' treatment). </p> <p>Had a given study randomised infants but provided the outcome data for eyes, we planned to contact the authors to obtain infant‐level data so as to avoid unit of analysis error; using eyes as the denominator without adjusting for non‐independence between the eyes can result in spuriously precise results, that is narrow confidence intervals similar to those seen in cluster randomised trials when the clusters are randomised but the outcomes are analysed at the individual level without adjusting for 'cluster' effect (<a href="./references#CD009734-bbs2-0034" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). If we could not obtain that information, we used the data for eyes but mentioned up‐front that the analysis referred to eyes and not infants. </p> </section> <section id="CD009734-sec-0047"> <h4 class="title">Dealing with missing data</h4> <p>At the outcome level, if the data were measured but not reported, we planned to request such data from the study authors. If there was a discrepancy in the number randomised and the number analysed in each treatment group, we calculated and reported the percentage lost to follow‐up in each group. </p> </section> <section id="CD009734-sec-0048"> <h4 class="title">Assessment of heterogeneity</h4> <p>We intended to assess heterogeneity between trial results by inspecting the forest plots and quantifying the impact of heterogeneity in any meta‐analysis using a measure of the degree of inconsistency in the studies’ results (<a href="./references#CD009734-bbs2-0027" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). </p> <p>We estimated the proportion of total statistical heterogeneity not explained by chance using the I<sup>2</sup> statistic (<a href="./references#CD009734-bbs2-0032" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). I<sup>2</sup> (calculated as I<sup>2</sup> = 100% x (Q ‐ df )/Q; where Q is Cochran’s heterogeneity statistic and df is the degrees of freedom) lies between 0% and 100%. </p> </section> <section id="CD009734-sec-0049"> <h4 class="title">Data synthesis</h4> <p>We entered quantitative data into Review Manager 5 and analysed the data using the standard methods of Cochrane and Cochrane Neonatal (<a href="./references#CD009734-bbs2-0044" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). We used the Mantel‐Haenszel method for estimates of typical RR and RD. We analysed continuous outcomes using the inverse variance method. </p> <section id="CD009734-sec-0050"> <h5 class="title">Quality of evidence</h5> <p>We used the GRADE approach, as outlined in the GRADE Handbook (<a href="./references#CD009734-bbs2-0045" title="SchünemannH , BrożekJ , GuyattG , OxmanA (editors) . Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. gdt.guidelinedevelopment.org/app/handbook/handbook.html (accessed prior to 12 December 2017). ">Schünemann 2013</a>), to assess the quality of evidence for the following (clinically relevant) outcomes. </p> <p> <ul id="CD009734-list-0013"> <li> <p>Structural outcome: retinal detachment</p> </li> <li> <p>Structural outcome: complete retinal detachment</p> </li> <li> <p>Refractive error: very high myopia at 30 months of age</p> </li> <li> <p>Mortality before discharge</p> </li> <li> <p>Mortality at 30 months of age</p> </li> <li> <p>Local adverse effects: corneal opacity requiring corneal transplant</p> </li> <li> <p>Local adverse effects: lens opacity requiring cataract removal</p> </li> <li> <p>Local adverse effects: perioperative retinal haemorrhages</p> </li> <li> <p>Recurrence of ROP</p> </li> </ul> </p> <p>Two review authors independently assessed the quality of the evidence for each of the outcomes above. We considered evidence from randomised controlled trials as high quality, but downgraded the evidence one level for serious (or two levels for very serious) limitations based upon the following: design (risk of bias), consistency across studies, directness of the evidence, precision of estimates, and presence of publication bias. We used GRADEpro GDT to create a ‘Summary of findings’ table to report the quality of the evidence (<a href="./references#CD009734-bbs2-0031" title="McMaster University (developed by Evidence Prime). Available at gradepro.org. GRADEpro GDT. Version (accessed 5 December 2017). Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org, 2015. ">GRADEpro GDT</a>). </p> <p>The GRADE approach results in an assessment of the quality of a body of evidence in one of four grades: </p> <p> <ol id="CD009734-list-0014"> <li> <p>High: We are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ol> </p> <p>We used GRADEpro GDT to import data from Review Manager 5 to create the 'Summary of findings' tables (<a href="./references#CD009734-bbs2-0031" title="McMaster University (developed by Evidence Prime). Available at gradepro.org. GRADEpro GDT. Version (accessed 5 December 2017). Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org, 2015. ">GRADEpro GDT</a>; <a href="./references#CD009734-bbs2-0044" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). These tables provide outcome‐specific information concerning the overall quality of evidence from studies included in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on the outcomes we considered. </p> </section> </section> <section id="CD009734-sec-0051"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Considerations of clinical diversity included assessment of differences in the nature of the surgical intervention, type and extent of disease, and the number and route of administration of VEGF inhibitors. Accordingly, we planned to analyse the studies based on differences in the following pre‐planned subgroups. </p> <p> <ul id="CD009734-list-0015"> <li> <p>Nature of retinal ablation procedure (cryotherapy versus laser therapy)</p> </li> <li> <p>Location of ROP at enrolment (zone I versus zone II)</p> </li> <li> <p>Severity of ROP at enrolment (aggressive posterior retinopathy of prematurity versus others) </p> </li> <li> <p>Specific anti‐VEGF agent administered</p> </li> <li> <p>Number of doses of anti‐VEGF drug (single versus multiple)</p> </li> <li> <p>Birth weights of the enrolled infants (&lt; 1250 g versus ≥ 1250 g)</p> </li> </ul> </p> </section> <section id="CD009734-sec-0052"> <h4 class="title">Sensitivity analysis</h4> <p>We intended to conduct a sensitivity analysis to investigate the robustness of the results for the primary outcome by excluding trials at high risk of bias or with dropout rates of more than 10% (overall). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009734-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009734-sec-0053"></div> <section id="CD009734-sec-0054"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD009734-sec-0128" title="">Characteristics of included studies</a> </p> <section id="CD009734-sec-0055"> <h4 class="title">Results of the search</h4> <p>Upon updating the search, we retrieved a total of 71 unique records, of which 58 were excluded after we scanned the title or abstract, or both (<a href="#CD009734-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD009734-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram: review update." data-id="CD009734-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram: review update.</p> </div> </div> </div> <p>Six randomised trials fulfilled the eligibility criteria and were included in the review (<a href="./references#CD009734-bbs2-0002" title="GeloneckMM , ChuangAZ , ClarkWL , HuntMG , NormanAA , PackwoodEA , et al. BEAT‐ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmology2014;132(11):1327‐33. [PUBMED: 25103848] Mintz‐HittnerHA , KennedyKA , ChuangAZ ,  BEAT‐ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New England Journal of Medicine2011;364(7):603‐15. [PUBMED: 21323540] NCT00622726 . Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT‐ROP). clinicaltrials.gov/ct2/show/NCT00622726 25 February 2008. ">BEAT‐ROP Trial 2011</a>; <a href="./references#CD009734-bbs2-0001" title="AutrataR , KrejčířováI , ŠenkováK , HoloušováM , DoleželZ , BorekI . Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. European Journal of Ophthalmology2012;22(5):687‐94. [PUBMED: 22669848] ">Autrata 2012</a>; <a href="./references#CD009734-bbs2-0004" title="LeporeD , QuinnGE , MolleF , BaldascinoA , OraziL , SammartinoM , et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology2014;121(11):2212‐9. [PUBMED: 25001158] ">Lepore 2014</a>; <a href="./references#CD009734-bbs2-0003" title="KarkhanehR , KhodabandeA , Riazi‐EafahaniM , RoohipoorR , GhassemiF , ImaniM , et al. Efficacy of intravitreal bevacizumab for zone‐II retinopathy of prematurity. Acta Ophthalmologica2016;94(6):e417‐20. [DOI: 10.1111/aos.13008; PUBMED: 27009449] ">Karkhaneh 2016</a>; <a href="./references#CD009734-bbs2-0005" title="O'KeeffeN , MurphyJ , O'KeefeM , LaniganB . Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up. Irish Medical Journal2016;109(2):355. [PUBMED: 27685689] ">O'Keeffe 2016</a>; <a href="./references#CD009734-bbs2-0006" title="ZhangG , YangM , ZengJ , VakrosG , SuK , ChenM , et al. Shenzhen Screening for Retinopathy of Prematurity Cooperative Group. Comparison of intravitreal injection of ranibuzumab versus laser therapy for zone II treatment‐requiring retinopathy of prematurity. Retina 2016 Aug 12 [Epub ahead of print]. [DOI: 10.1097/IAE.0000000000001241; PUBMED: 27529839] ">Zhang 2016</a>). Three articles remain in 'Studies awaiting classification'. </p> </section> <section id="CD009734-sec-0056"> <h4 class="title">Included studies</h4> <p>Of the six included studies, four compared intravitreal bevacizumab monotherapy with conventional laser therapy (<a href="./references#CD009734-bbs2-0002" title="GeloneckMM , ChuangAZ , ClarkWL , HuntMG , NormanAA , PackwoodEA , et al. BEAT‐ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmology2014;132(11):1327‐33. [PUBMED: 25103848] Mintz‐HittnerHA , KennedyKA , ChuangAZ ,  BEAT‐ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New England Journal of Medicine2011;364(7):603‐15. [PUBMED: 21323540] NCT00622726 . Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT‐ROP). clinicaltrials.gov/ct2/show/NCT00622726 25 February 2008. ">BEAT‐ROP Trial 2011</a>; <a href="./references#CD009734-bbs2-0004" title="LeporeD , QuinnGE , MolleF , BaldascinoA , OraziL , SammartinoM , et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology2014;121(11):2212‐9. [PUBMED: 25001158] ">Lepore 2014</a>; <a href="./references#CD009734-bbs2-0003" title="KarkhanehR , KhodabandeA , Riazi‐EafahaniM , RoohipoorR , GhassemiF , ImaniM , et al. Efficacy of intravitreal bevacizumab for zone‐II retinopathy of prematurity. Acta Ophthalmologica2016;94(6):e417‐20. [DOI: 10.1111/aos.13008; PUBMED: 27009449] ">Karkhaneh 2016</a>; <a href="./references#CD009734-bbs2-0005" title="O'KeeffeN , MurphyJ , O'KeefeM , LaniganB . Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up. Irish Medical Journal2016;109(2):355. [PUBMED: 27685689] ">O'Keeffe 2016</a>); one compared ranibizumab monotherapy with laser therapy (<a href="./references#CD009734-bbs2-0006" title="ZhangG , YangM , ZengJ , VakrosG , SuK , ChenM , et al. Shenzhen Screening for Retinopathy of Prematurity Cooperative Group. Comparison of intravitreal injection of ranibuzumab versus laser therapy for zone II treatment‐requiring retinopathy of prematurity. Retina 2016 Aug 12 [Epub ahead of print]. [DOI: 10.1097/IAE.0000000000001241; PUBMED: 27529839] ">Zhang 2016</a>); and one study compared intravitreal pegaptanib plus conventional laser therapy with laser and cryotherapy (<a href="./references#CD009734-bbs2-0001" title="AutrataR , KrejčířováI , ŠenkováK , HoloušováM , DoleželZ , BorekI . Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. European Journal of Ophthalmology2012;22(5):687‐94. [PUBMED: 22669848] ">Autrata 2012</a>). Four trials randomised the infants (<a href="./references#CD009734-bbs2-0002" title="GeloneckMM , ChuangAZ , ClarkWL , HuntMG , NormanAA , PackwoodEA , et al. BEAT‐ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmology2014;132(11):1327‐33. [PUBMED: 25103848] Mintz‐HittnerHA , KennedyKA , ChuangAZ ,  BEAT‐ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New England Journal of Medicine2011;364(7):603‐15. [PUBMED: 21323540] NCT00622726 . Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT‐ROP). clinicaltrials.gov/ct2/show/NCT00622726 25 February 2008. ">BEAT‐ROP Trial 2011</a>; <a href="./references#CD009734-bbs2-0001" title="AutrataR , KrejčířováI , ŠenkováK , HoloušováM , DoleželZ , BorekI . Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. European Journal of Ophthalmology2012;22(5):687‐94. [PUBMED: 22669848] ">Autrata 2012</a>; <a href="./references#CD009734-bbs2-0003" title="KarkhanehR , KhodabandeA , Riazi‐EafahaniM , RoohipoorR , GhassemiF , ImaniM , et al. Efficacy of intravitreal bevacizumab for zone‐II retinopathy of prematurity. Acta Ophthalmologica2016;94(6):e417‐20. [DOI: 10.1111/aos.13008; PUBMED: 27009449] ">Karkhaneh 2016</a>; <a href="./references#CD009734-bbs2-0006" title="ZhangG , YangM , ZengJ , VakrosG , SuK , ChenM , et al. Shenzhen Screening for Retinopathy of Prematurity Cooperative Group. Comparison of intravitreal injection of ranibuzumab versus laser therapy for zone II treatment‐requiring retinopathy of prematurity. Retina 2016 Aug 12 [Epub ahead of print]. [DOI: 10.1097/IAE.0000000000001241; PUBMED: 27529839] ">Zhang 2016</a>), while the other two trials randomised the eyes of the infants to the two groups (<a href="./references#CD009734-bbs2-0004" title="LeporeD , QuinnGE , MolleF , BaldascinoA , OraziL , SammartinoM , et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology2014;121(11):2212‐9. [PUBMED: 25001158] ">Lepore 2014</a>; <a href="./references#CD009734-bbs2-0005" title="O'KeeffeN , MurphyJ , O'KeefeM , LaniganB . Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up. Irish Medical Journal2016;109(2):355. [PUBMED: 27685689] ">O'Keeffe 2016</a>). Two studies enrolled infants with only zone II ROP (<a href="./references#CD009734-bbs2-0003" title="KarkhanehR , KhodabandeA , Riazi‐EafahaniM , RoohipoorR , GhassemiF , ImaniM , et al. Efficacy of intravitreal bevacizumab for zone‐II retinopathy of prematurity. Acta Ophthalmologica2016;94(6):e417‐20. [DOI: 10.1111/aos.13008; PUBMED: 27009449] ">Karkhaneh 2016</a>; <a href="./references#CD009734-bbs2-0006" title="ZhangG , YangM , ZengJ , VakrosG , SuK , ChenM , et al. Shenzhen Screening for Retinopathy of Prematurity Cooperative Group. Comparison of intravitreal injection of ranibuzumab versus laser therapy for zone II treatment‐requiring retinopathy of prematurity. Retina 2016 Aug 12 [Epub ahead of print]. [DOI: 10.1097/IAE.0000000000001241; PUBMED: 27529839] ">Zhang 2016</a>), while one study included those with zone I ROP only (<a href="./references#CD009734-bbs2-0004" title="LeporeD , QuinnGE , MolleF , BaldascinoA , OraziL , SammartinoM , et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology2014;121(11):2212‐9. [PUBMED: 25001158] ">Lepore 2014</a>); the remaining three studies enrolled infants with either zone I or zone II ROP (<a href="./references#CD009734-bbs2-0002" title="GeloneckMM , ChuangAZ , ClarkWL , HuntMG , NormanAA , PackwoodEA , et al. BEAT‐ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmology2014;132(11):1327‐33. [PUBMED: 25103848] Mintz‐HittnerHA , KennedyKA , ChuangAZ ,  BEAT‐ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New England Journal of Medicine2011;364(7):603‐15. [PUBMED: 21323540] NCT00622726 . Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT‐ROP). clinicaltrials.gov/ct2/show/NCT00622726 25 February 2008. ">BEAT‐ROP Trial 2011</a>; <a href="./references#CD009734-bbs2-0001" title="AutrataR , KrejčířováI , ŠenkováK , HoloušováM , DoleželZ , BorekI . Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. European Journal of Ophthalmology2012;22(5):687‐94. [PUBMED: 22669848] ">Autrata 2012</a>; <a href="./references#CD009734-bbs2-0005" title="O'KeeffeN , MurphyJ , O'KeefeM , LaniganB . Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up. Irish Medical Journal2016;109(2):355. [PUBMED: 27685689] ">O'Keeffe 2016</a>). Two trials allowed cross‐over treatment for infants with recurrence/reactivation of ROP (i.e. laser therapy for bevacizumab group and vice versa) (<a href="./references#CD009734-bbs2-0005" title="O'KeeffeN , MurphyJ , O'KeefeM , LaniganB . Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up. Irish Medical Journal2016;109(2):355. [PUBMED: 27685689] ">O'Keeffe 2016</a>; <a href="./references#CD009734-bbs2-0006" title="ZhangG , YangM , ZengJ , VakrosG , SuK , ChenM , et al. Shenzhen Screening for Retinopathy of Prematurity Cooperative Group. Comparison of intravitreal injection of ranibuzumab versus laser therapy for zone II treatment‐requiring retinopathy of prematurity. Retina 2016 Aug 12 [Epub ahead of print]. [DOI: 10.1097/IAE.0000000000001241; PUBMED: 27529839] ">Zhang 2016</a>). </p> <p><a href="./references#CD009734-bbs2-0002" title="GeloneckMM , ChuangAZ , ClarkWL , HuntMG , NormanAA , PackwoodEA , et al. BEAT‐ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmology2014;132(11):1327‐33. [PUBMED: 25103848] Mintz‐HittnerHA , KennedyKA , ChuangAZ ,  BEAT‐ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New England Journal of Medicine2011;364(7):603‐15. [PUBMED: 21323540] NCT00622726 . Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT‐ROP). clinicaltrials.gov/ct2/show/NCT00622726 25 February 2008. ">BEAT‐ROP Trial 2011</a> was a multicentre randomised trial conducted at 15 hospitals in the USA (<a href="./references#CD009734-bbs2-0002" title="GeloneckMM , ChuangAZ , ClarkWL , HuntMG , NormanAA , PackwoodEA , et al. BEAT‐ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmology2014;132(11):1327‐33. [PUBMED: 25103848] Mintz‐HittnerHA , KennedyKA , ChuangAZ ,  BEAT‐ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New England Journal of Medicine2011;364(7):603‐15. [PUBMED: 21323540] NCT00622726 . Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT‐ROP). clinicaltrials.gov/ct2/show/NCT00622726 25 February 2008. ">BEAT‐ROP Trial 2011</a>). It enrolled 150 preterm infants with zone I or zone II posterior stage 3+ ROP and randomly assigned them to receive intravitreal bevacizumab (0.625 mg in 0.025 mL of solution) or conventional laser therapy, bilaterally. The primary outcome was treatment failure, defined as the recurrence of neovascularisation in one or both eyes requiring retreatment, by 54 weeks’ postmenstrual age. RetCam (retinal imaging) photographs taken at different time points were evaluated to document recurrence of ROP. The study investigators reported the refractive outcomes at 30 months of age in a separate publication in 2014 by Geloneck (see <a href="./references#CD009734-bbs2-0002" title="GeloneckMM , ChuangAZ , ClarkWL , HuntMG , NormanAA , PackwoodEA , et al. BEAT‐ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmology2014;132(11):1327‐33. [PUBMED: 25103848] Mintz‐HittnerHA , KennedyKA , ChuangAZ ,  BEAT‐ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New England Journal of Medicine2011;364(7):603‐15. [PUBMED: 21323540] NCT00622726 . Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT‐ROP). clinicaltrials.gov/ct2/show/NCT00622726 25 February 2008. ">BEAT‐ROP Trial 2011</a>). Of the originally enrolled 150 infants, 131 infants underwent cycloplegic retinoscopic refraction to assess refractive outcomes at this age. </p> <p><a href="./references#CD009734-bbs2-0001" title="AutrataR , KrejčířováI , ŠenkováK , HoloušováM , DoleželZ , BorekI . Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. European Journal of Ophthalmology2012;22(5):687‐94. [PUBMED: 22669848] ">Autrata 2012</a> enrolled 76 preterm infants with zone I or zone II posterior stage 3+ ROP, admitted in a university hospital in the Czech Republic. Enrolled infants were randomly assigned to receive intravitreal pegaptanib (0.3 mg in 0.02 mL of solution) plus conventional diode laser therapy or laser therapy combined with cryotherapy, bilaterally. The primary outcome was treatment success, defined as absence of recurrence of stage 3+ ROP in one or both eyes by 55 weeks' postmenstrual age. RetCam photographs taken at different time points were evaluated to document recurrence of ROP. Infants who were randomised to the intervention group and had recurrence were given an additional intravitreal pegaptanib injection; those in the laser‐plus‐cryotherapy group did not receive pegaptanib for recurrence. </p> <p><a href="./references#CD009734-bbs2-0003" title="KarkhanehR , KhodabandeA , Riazi‐EafahaniM , RoohipoorR , GhassemiF , ImaniM , et al. Efficacy of intravitreal bevacizumab for zone‐II retinopathy of prematurity. Acta Ophthalmologica2016;94(6):e417‐20. [DOI: 10.1111/aos.13008; PUBMED: 27009449] ">Karkhaneh 2016</a> enrolled 79 preterm infants (158 eyes) with zone II/stage 2 or 3 ROP and plus disease in a tertiary referral hospital in Tehran, Iran. Of them, 43 infants (86 eyes) were assigned to receive intravitreal bevacizumab injections (0.625 mg/0.025 mL) and 36 infants (72 eyes) were assigned to receive conventional indirect laser therapy. The primary outcome was defined as treatment failure, that is ROP persistence or recurrence by 90 weeks' postmenstrual age. Three experienced retina specialists (who were not involved in the initial treatment) performed follow‐up visits. </p> <p><a href="./references#CD009734-bbs2-0005" title="O'KeeffeN , MurphyJ , O'KeefeM , LaniganB . Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up. Irish Medical Journal2016;109(2):355. [PUBMED: 27685689] ">O'Keeffe 2016</a> conducted a prospective randomised study in 15 preterm infants with zone I or posterior zone II ROP admitted in a hospital in Dublin, Ireland. One eye of each infant was randomised to intravitreal bevacizumab, while the other eye was allocated to diode laser therapy. The investigators followed complications, regression/reactivation of ROP, visual outcome, refractive error, and systemic complications until five years of age. </p> <p><a href="./references#CD009734-bbs2-0006" title="ZhangG , YangM , ZengJ , VakrosG , SuK , ChenM , et al. Shenzhen Screening for Retinopathy of Prematurity Cooperative Group. Comparison of intravitreal injection of ranibuzumab versus laser therapy for zone II treatment‐requiring retinopathy of prematurity. Retina 2016 Aug 12 [Epub ahead of print]. [DOI: 10.1097/IAE.0000000000001241; PUBMED: 27529839] ">Zhang 2016</a> conducted a randomised controlled trial of 50 infants with zone II treatment‐requiring ROP (i.e. stage 2 or 3 ROP with plus disease) admitted in the participating hospitals of 'Shenzhen Screening for ROP Cooperative Group', Shenzen, China.<br/> Infants were randomly assigned to receive intravitreal injection of ranibizumab monotherapy or laser therapy. Follow‐up interval was at least six months. Any eyes that developed recurrence of ROP underwent cross‐over retreatment. </p> <p><a href="./references#CD009734-bbs2-0004" title="LeporeD , QuinnGE , MolleF , BaldascinoA , OraziL , SammartinoM , et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology2014;121(11):2212‐9. [PUBMED: 25001158] ">Lepore 2014</a> conducted a single‐centre randomised trial and enrolled 13 infants with type 1 ROP in zone I in both eyes who required treatment according to Early Treatment for Retinopathy of Prematurity (ETROP) criteria (<a href="./references#CD009734-bbs2-0028" title="Early Treatment for Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy Of Prematurity randomized trial. Archives of Ophthalmology2003;121(12):1684‐94. [PUBMED: 14662586] ">ETROP Group 2003</a>). One eye of the enrolled infants was randomised to receive an intravitreal injection of 0.5 mg bevacizumab, while the fellow eye received conventional laser photoablation. The eye assigned to conventional laser peripheral ablation was treated first. The primary outcome was presence of retinal and choroidal abnormalities on fluorescein angiography at nine months of age. After treatment, binocular indirect ophthalmoscopy and RetCam imaging were performed every three days, and fluorescein angiography was performed every two weeks until discharge. Fluorescein angiography was done again at nine months of age under general anaesthesia. </p> <p>Further details of the six studies are provided in the <a href="./references#CD009734-sec-0128" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD009734-sec-0057"> <h4 class="title">Excluded studies</h4> <p>We identified a large number of publications that were retrospective studies/case series of treatment with anti‐VEGF. For brevity, only the studies that provided data hitherto unreported in the randomised trials included in the review ‐ such as those comparing bevacizumab with ranibizumab, evaluating long‐term neurodevelopmental outcomes, etc. ‐ are mentioned here. </p> <p><a href="./references#CD009734-bbs2-0007" title="Alyamac SukgenE , ComezA , KoclukY , CevherS . The process of retinal vascularization after anti‐VEGF treatment in retinopathy of prematurity: a comparison study between ranibizumab and bevacizumab. Ophthalmologica. Journal International d'Ophtalmologie [International Journal of Ophthalmology]2016;236(3):139‐47. [DOI: 10.1159/000449530; PUBMED: 27682852] ">Alyamac 2016</a> reported a two‐centre retrospective study to compare the effects on the process of retinal vascularisation of intravitreal ranibizumab (IVR) and intravitreal bevacizumab (IVB) in the treatment of severe ROP. Forty‐four eyes of 22 participants in group 1 were applied 0.625 mg bevacizumab, and 46 eyes of 23 participants in group 2 were applied 0.25 mg ranibizumab. Retinal vascularisation was evaluated clinically. </p> <p><a href="./references#CD009734-bbs2-0008" title="Araz‐ErsanB , KirN , TuncerS , Aydinoglu‐CandanO , Yildiz‐InecD , AkdoganB , et al. Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. Current Eye Research2015;40(6):585‐91. [DOI: 10.3109/02713683.2014.941070; PUBMED: 25025864] ">Araz‐Ersan 2015</a> conducted a longitudinal follow‐up study of preterm infants who received 0.625 mg IVB therapy in addition to standard laser photocoagulation therapy. For comparison of the ophthalmological and neurological assessment outcomes of these infants, a control group was formed with 13 birth weight‐ and gestational age‐matched infants who were treated with laser therapy alone for type 1 ROP. The neurological status of the study group and the control group was examined systematically, and neurodevelopmental evaluation was assessed by the Bayley Scales of Infant Development (BSID‐III). The study included a total of 18 eyes of 13 infants. </p> <p><a href="./references#CD009734-bbs2-0010" title="ErolMK , CobanDT , SariES , BilginAB , DoganB , OzdemirO , et al. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity. Arquivos Brasileiros de Oftalmologia2015;78(6):340‐3. [DOI: 10.5935/0004‐2749.20150090; PUBMED: 26677033] ">Erol 2015</a> reported a retrospective evaluation of 36 eyes of 20 participants with type 1 ROP who received anti‐VEGF intravitreal injections between August 2011 and February 2013. Fifteen eyes of 8 participants received 0.25 mg ranibizumab (group 1), and 21 eyes of 12 participants received 0.625 mg bevacizumab (group 2). Eyes were examined by indirect ophthalmoscopy on the first day, third day, first week, and first month and as required after injections. Laser photocoagulation was performed in cases with progression of ROP. </p> <p><a href="./references#CD009734-bbs2-0011" title="GunayM , SukgenEA , CelikG , KoclukY . Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey. Current Eye Research2016;42(3):462‐9. [DOI: 10.1080/02713683.2016.1196709; PUBMED: 27420302] ">Gunay 2016</a> conducted a retrospective interventional case series study including the data of 134 infants (264 eyes) who were treated with IVB, IVR, or laser photocoagulation for ROP. The data were collected from two major ROP treatment centres in Turkey without any randomisation or masking. Regression of ROP, recurrence profile, complications after each treatment modality, and indications for retreatment were evaluated. The main outcome measures included the total inactivation of ROP with anatomic and refractive outcomes at 1.5 years of adjusted age. There were 55 infants (41.1%) in the IVB group, 22 infants (16.4%) in the IVR group, and 57 infants (42.5%) in the laser photocoagulation group. </p> <p><a href="./references#CD009734-bbs2-0012" title="HanJ , KimSE , LeeSC , LeeCS . Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired‐eye comparison. Acta Ophthalmologica 2016 Mar 24 [Epub ahead of print]. [DOI: 10.1111/aos.13004; PUBMED: 27011262] ">Han 2016</a> reported a case series addressing the clinical outcomes of IVB injection, with different dosing (0.25 mg/0.01 mL versus 0.625 mg/0.025 mL) in each eye of the same participant with ROP. Intravitreal bevacizumab was injected into 8 participants with stage 3+ in zone I or posterior zone II ROP (16 eyes). Different doses of bevacizumab (0.25 mg/0.01 mL and 0.625 mg/0.025 mL) were injected into the vitreous cavity of each eye. </p> <p><a href="./references#CD009734-bbs2-0013" title="KabatasEU , KurtulBE , Altiaylik OzerP , KabatasN . Comparison of intravitreal bevacizumab, intravitreal ranibizumab and laser photocoagulation for treatment of type 1 retinopathy of prematurity in Turkish preterm children. Current Eye Research 2017 Jan 27 [Epub ahead of print]. [DOI: 10.1080/02713683.2016.1264607; PUBMED: 28128986] ">Kabatas 2017</a> conducted a review of infants treated for ROP to evaluate the effectiveness of treatment modalities, major complications, and refractive errors in children who were treated with IVB, IVR, or laser photocoagulation for type 1 ROP. Preterm infants who underwent IVB monotherapy (group 1, 24 eyes of 12 infants), IVR monotherapy (group 2, 12 eyes of 6 infants), or laser photocoagulation (group 3, 72 eyes of 36 infants) for type 1 ROP and infants with spontaneously regressed ROP (group 4, 148 eyes of 74 infants) were included in the study. The study evaluated major complications, recurrence rate, recurrence time, total retinal vascularisation time, and refractive errors at 18 months of corrected age. </p> <p><a href="./references#CD009734-bbs2-0014" title="LienR , YuMH , HsuKH , LiaoPJ , ChenYP , LaiCC , et al. Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment. PLoS ONE2016;11(1):e0148019. [DOI: 10.1371/journal.pone.0148019; PUBMED: 26815000] ">Lien 2016</a> conducted a retrospective observational case series at an institutional referral centre. The purpose of the study was to investigate the neurodevelopment of preterm infants after IVB for the treatment of ROP up to the two years of age. Infants with type 1 ROP were classified into three groups: laser only, IVB only, and a combination of IVB and laser treatment. Main outcome measures were neurodevelopmental outcomes of the infants after treatment assessed by BSID. Sixty‐one infants for whom the neurodevelopmental survey was finished were included. </p> <p><a href="./references#CD009734-bbs2-0015" title="LinCJ , TsaiYY . Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity. Clinical Ophthalmology (Auckland, NZ)2016;10:1323‐7. [DOI: 10.2147/OPTH.S110717; PUBMED: 27499611] ">Lin 2016</a> conducted a comparative, consecutive case study reporting on the axial length, refraction, and retinal vascularisation one year after ranibizumab or bevacizumab treatment for threshold ROP. Twenty‐five eyes of 13 participants with threshold ROP received one IVR treatment, and 15 eyes of eight participants received one IVB treatment. </p> <p><a href="./references#CD009734-bbs2-0016" title="MorinJ , LuuTM , SupersteinR , OspinaLH , LefebvreF , SimardMN , et al. Canadian Neonatal Network and the Canadian Neonatal Follow‐Up Network Investigators. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics2016;137(4):e20153218. [DOI: 10.1542/peds.2015‐3218; PUBMED: 27244705] ">Morin 2016</a> retrospectively reviewed data from the Canadian Neonatal Network and the Canadian Neonatal Follow‐Up Network databases on infants born at less than 29 weeks' gestation in 2010 to 2011 and treated for ROP. Neurodevelopmental outcome at 18 months was assessed by neurologic examination and the Bayley Scales of Infant and Toddler Development, Third Edition. </p> <p><a href="./references#CD009734-bbs2-0017" title="WongRK , HubschmanS , TsuiI . Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina (Philadelphia, Pa.)2015;35(4):675‐80. [DOI: 10.1097/IAE.0000000000000578; PUBMED: 25768252] ">Wong 2015</a> reported a retrospective chart review on consecutive infants screened for ROP. Infants treated with peripheral retinal ablation, bevacizumab 0.625 mg/0.025 mL, or ranibizumab 0.25 mg/0.025 mL were specifically identified for review of their clinical outcomes. All treated infants had at least six months of follow‐up with the treating team and were examined until total regression of ROP. One hundred and forty‐two infants were screened over a two‐year period. Six infants with a mean gestational age of 23.48 weeks and mean birth weight of 620 g received anti‐VEGF agents. Ten eyes from the six infants received anti‐VEGF treatment. </p> <section id="CD009734-sec-0058"> <h5 class="title">Awaiting further assessment</h5> <p>The studies of <a href="./references#CD009734-bbs2-0018" title="AutrataR , SenkovaK , HolousovaM , KrejcirovaI , DolezelZ , BorekI . Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II ‐ four years results [Prinos intravitrealni aplikace anti‐VEGF preparatu v lecbe prahoveho stadia ROP 3+ v zone I‐II: vysledky ctyrlete studie]. Ceska a Slovenska Oftalmologie2012;68(1):29‐36. ">Autrata 2012a</a>, <a href="./references#CD009734-bbs2-0019" title="KongL , BhattAR , DemnyAB , CoatsDK , LiA , RahmanEZ , et al. Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF‐1 in infants with retinopathy of prematurity. Investigative Ophthalmology &amp; Visual Science2015;56(2):956‐61. [DOI: 10.1167/iovs.14‐15842; PUBMED: 25613938] ">Kong 2015</a>, and <a href="./references#CD009734-bbs2-0020" title="MoranS , O'KeefeM , HartnettC , LaniganB , MurphyJ , DonoghueV . Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity. Acta Ophthalmologica2014; Vol. 92, issue 6:e496‐7. [DOI: 10.1111/aos.12339; PUBMED: 24428792] ">Moran 2014</a> are awaiting further assessment. </p> </section> </section> </section> <section id="CD009734-sec-0059"> <h3 class="title">Risk of bias in included studies</h3> <p>Risk of bias assessments are detailed in the <a href="./references#CD009734-sec-0128" title="">Characteristics of included studies</a> table and are summarised in <a href="#CD009734-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD009734-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009734-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009734-sec-0060"> <h4 class="title">Allocation</h4> <p>Only one trial reported an adequate allocation concealment method (<a href="./references#CD009734-bbs2-0002" title="GeloneckMM , ChuangAZ , ClarkWL , HuntMG , NormanAA , PackwoodEA , et al. BEAT‐ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmology2014;132(11):1327‐33. [PUBMED: 25103848] Mintz‐HittnerHA , KennedyKA , ChuangAZ ,  BEAT‐ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New England Journal of Medicine2011;364(7):603‐15. [PUBMED: 21323540] NCT00622726 . Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT‐ROP). clinicaltrials.gov/ct2/show/NCT00622726 25 February 2008. ">BEAT‐ROP Trial 2011</a>); details of allocation concealment were not reported in the remaining studies (<a href="./references#CD009734-bbs2-0001" title="AutrataR , KrejčířováI , ŠenkováK , HoloušováM , DoleželZ , BorekI . Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. European Journal of Ophthalmology2012;22(5):687‐94. [PUBMED: 22669848] ">Autrata 2012</a>; <a href="./references#CD009734-bbs2-0004" title="LeporeD , QuinnGE , MolleF , BaldascinoA , OraziL , SammartinoM , et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology2014;121(11):2212‐9. [PUBMED: 25001158] ">Lepore 2014</a>; <a href="./references#CD009734-bbs2-0003" title="KarkhanehR , KhodabandeA , Riazi‐EafahaniM , RoohipoorR , GhassemiF , ImaniM , et al. Efficacy of intravitreal bevacizumab for zone‐II retinopathy of prematurity. Acta Ophthalmologica2016;94(6):e417‐20. [DOI: 10.1111/aos.13008; PUBMED: 27009449] ">Karkhaneh 2016</a>; <a href="./references#CD009734-bbs2-0005" title="O'KeeffeN , MurphyJ , O'KeefeM , LaniganB . Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up. Irish Medical Journal2016;109(2):355. [PUBMED: 27685689] ">O'Keeffe 2016</a>; <a href="./references#CD009734-bbs2-0006" title="ZhangG , YangM , ZengJ , VakrosG , SuK , ChenM , et al. Shenzhen Screening for Retinopathy of Prematurity Cooperative Group. Comparison of intravitreal injection of ranibuzumab versus laser therapy for zone II treatment‐requiring retinopathy of prematurity. Retina 2016 Aug 12 [Epub ahead of print]. [DOI: 10.1097/IAE.0000000000001241; PUBMED: 27529839] ">Zhang 2016</a>). </p> </section> <section id="CD009734-sec-0061"> <h4 class="title">Blinding</h4> <p>Given the nature of the intervention, masking (blinding) of the intervention was not possible in any of the included studies. </p> <p><a href="./references#CD009734-bbs2-0002" title="GeloneckMM , ChuangAZ , ClarkWL , HuntMG , NormanAA , PackwoodEA , et al. BEAT‐ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmology2014;132(11):1327‐33. [PUBMED: 25103848] Mintz‐HittnerHA , KennedyKA , ChuangAZ ,  BEAT‐ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New England Journal of Medicine2011;364(7):603‐15. [PUBMED: 21323540] NCT00622726 . Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT‐ROP). clinicaltrials.gov/ct2/show/NCT00622726 25 February 2008. ">BEAT‐ROP Trial 2011</a> formed a panel of six independent experts to examine the photographs taken at 54 weeks' postmenstrual age, and masked them to the treatment assignments by cropping the photographs to include only the optic disk and macula without laser marks. This enabled the study investigators to perform masked assessment of some of the secondary outcomes (e.g. macular dragging) but not the primary outcome of the study. Paediatric ophthalmologists who performed the cycloplegic retinoscopic refractions to assess the refractive errors at 30 months of age were not masked to the treatment assignments. In <a href="./references#CD009734-bbs2-0003" title="KarkhanehR , KhodabandeA , Riazi‐EafahaniM , RoohipoorR , GhassemiF , ImaniM , et al. Efficacy of intravitreal bevacizumab for zone‐II retinopathy of prematurity. Acta Ophthalmologica2016;94(6):e417‐20. [DOI: 10.1111/aos.13008; PUBMED: 27009449] ">Karkhaneh 2016</a>, all follow‐up visits were performed by three experienced retina specialists who were not involved in the initial treatment. However it remains unclear if the outcome assessors were truly masked to the groups, as experienced ophthalmologists could potentially identify the spots left by laser therapy in the control group. </p> <p>It is not clear if the outcome assessors were masked to the group allocation in the other trials (<a href="./references#CD009734-bbs2-0001" title="AutrataR , KrejčířováI , ŠenkováK , HoloušováM , DoleželZ , BorekI . Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. European Journal of Ophthalmology2012;22(5):687‐94. [PUBMED: 22669848] ">Autrata 2012</a>; <a href="./references#CD009734-bbs2-0004" title="LeporeD , QuinnGE , MolleF , BaldascinoA , OraziL , SammartinoM , et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology2014;121(11):2212‐9. [PUBMED: 25001158] ">Lepore 2014</a>; <a href="./references#CD009734-bbs2-0005" title="O'KeeffeN , MurphyJ , O'KeefeM , LaniganB . Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up. Irish Medical Journal2016;109(2):355. [PUBMED: 27685689] ">O'Keeffe 2016</a>; <a href="./references#CD009734-bbs2-0006" title="ZhangG , YangM , ZengJ , VakrosG , SuK , ChenM , et al. Shenzhen Screening for Retinopathy of Prematurity Cooperative Group. Comparison of intravitreal injection of ranibuzumab versus laser therapy for zone II treatment‐requiring retinopathy of prematurity. Retina 2016 Aug 12 [Epub ahead of print]. [DOI: 10.1097/IAE.0000000000001241; PUBMED: 27529839] ">Zhang 2016</a>). </p> </section> <section id="CD009734-sec-0062"> <h4 class="title">Incomplete outcome data</h4> <p>Three trials reported no loss to follow‐up until 54 weeks' postmenstrual age (<a href="./references#CD009734-bbs2-0002" title="GeloneckMM , ChuangAZ , ClarkWL , HuntMG , NormanAA , PackwoodEA , et al. BEAT‐ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmology2014;132(11):1327‐33. [PUBMED: 25103848] Mintz‐HittnerHA , KennedyKA , ChuangAZ ,  BEAT‐ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New England Journal of Medicine2011;364(7):603‐15. [PUBMED: 21323540] NCT00622726 . Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT‐ROP). clinicaltrials.gov/ct2/show/NCT00622726 25 February 2008. ">BEAT‐ROP Trial 2011</a>; <a href="./references#CD009734-bbs2-0001" title="AutrataR , KrejčířováI , ŠenkováK , HoloušováM , DoleželZ , BorekI . Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. European Journal of Ophthalmology2012;22(5):687‐94. [PUBMED: 22669848] ">Autrata 2012</a>; <a href="./references#CD009734-bbs2-0003" title="KarkhanehR , KhodabandeA , Riazi‐EafahaniM , RoohipoorR , GhassemiF , ImaniM , et al. Efficacy of intravitreal bevacizumab for zone‐II retinopathy of prematurity. Acta Ophthalmologica2016;94(6):e417‐20. [DOI: 10.1111/aos.13008; PUBMED: 27009449] ">Karkhaneh 2016</a>). Two trials reported no loss to follow‐up at six to nine months of age (<a href="./references#CD009734-bbs2-0004" title="LeporeD , QuinnGE , MolleF , BaldascinoA , OraziL , SammartinoM , et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology2014;121(11):2212‐9. [PUBMED: 25001158] ">Lepore 2014</a>; <a href="./references#CD009734-bbs2-0006" title="ZhangG , YangM , ZengJ , VakrosG , SuK , ChenM , et al. Shenzhen Screening for Retinopathy of Prematurity Cooperative Group. Comparison of intravitreal injection of ranibuzumab versus laser therapy for zone II treatment‐requiring retinopathy of prematurity. Retina 2016 Aug 12 [Epub ahead of print]. [DOI: 10.1097/IAE.0000000000001241; PUBMED: 27529839] ">Zhang 2016</a>), while one trial reported no loss until five years of age (<a href="./references#CD009734-bbs2-0005" title="O'KeeffeN , MurphyJ , O'KeefeM , LaniganB . Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up. Irish Medical Journal2016;109(2):355. [PUBMED: 27685689] ">O'Keeffe 2016</a>). In one trial (<a href="./references#CD009734-bbs2-0002" title="GeloneckMM , ChuangAZ , ClarkWL , HuntMG , NormanAA , PackwoodEA , et al. BEAT‐ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmology2014;132(11):1327‐33. [PUBMED: 25103848] Mintz‐HittnerHA , KennedyKA , ChuangAZ ,  BEAT‐ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New England Journal of Medicine2011;364(7):603‐15. [PUBMED: 21323540] NCT00622726 . Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT‐ROP). clinicaltrials.gov/ct2/show/NCT00622726 25 February 2008. ">BEAT‐ROP Trial 2011</a>), about 17% of eligible infants were lost to follow‐up at 30 months of age. </p> </section> <section id="CD009734-sec-0063"> <h4 class="title">Selective reporting</h4> <p><a href="./references#CD009734-bbs2-0002" title="GeloneckMM , ChuangAZ , ClarkWL , HuntMG , NormanAA , PackwoodEA , et al. BEAT‐ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmology2014;132(11):1327‐33. [PUBMED: 25103848] Mintz‐HittnerHA , KennedyKA , ChuangAZ ,  BEAT‐ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New England Journal of Medicine2011;364(7):603‐15. [PUBMED: 21323540] NCT00622726 . Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT‐ROP). clinicaltrials.gov/ct2/show/NCT00622726 25 February 2008. ">BEAT‐ROP Trial 2011</a> reported all outcomes listed in the protocol (see NCT00622726 in <a href="./references#CD009734-bbs2-0002" title="GeloneckMM , ChuangAZ , ClarkWL , HuntMG , NormanAA , PackwoodEA , et al. BEAT‐ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmology2014;132(11):1327‐33. [PUBMED: 25103848] Mintz‐HittnerHA , KennedyKA , ChuangAZ ,  BEAT‐ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New England Journal of Medicine2011;364(7):603‐15. [PUBMED: 21323540] NCT00622726 . Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT‐ROP). clinicaltrials.gov/ct2/show/NCT00622726 25 February 2008. ">BEAT‐ROP Trial 2011</a>). We assessed the other trials as being at unclear risk of reporting bias. We could not refer to the study protocol of <a href="./references#CD009734-bbs2-0001" title="AutrataR , KrejčířováI , ŠenkováK , HoloušováM , DoleželZ , BorekI . Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. European Journal of Ophthalmology2012;22(5):687‐94. [PUBMED: 22669848] ">Autrata 2012</a>, <a href="./references#CD009734-bbs2-0003" title="KarkhanehR , KhodabandeA , Riazi‐EafahaniM , RoohipoorR , GhassemiF , ImaniM , et al. Efficacy of intravitreal bevacizumab for zone‐II retinopathy of prematurity. Acta Ophthalmologica2016;94(6):e417‐20. [DOI: 10.1111/aos.13008; PUBMED: 27009449] ">Karkhaneh 2016</a>, <a href="./references#CD009734-bbs2-0005" title="O'KeeffeN , MurphyJ , O'KeefeM , LaniganB . Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up. Irish Medical Journal2016;109(2):355. [PUBMED: 27685689] ">O'Keeffe 2016</a>, and <a href="./references#CD009734-bbs2-0006" title="ZhangG , YangM , ZengJ , VakrosG , SuK , ChenM , et al. Shenzhen Screening for Retinopathy of Prematurity Cooperative Group. Comparison of intravitreal injection of ranibuzumab versus laser therapy for zone II treatment‐requiring retinopathy of prematurity. Retina 2016 Aug 12 [Epub ahead of print]. [DOI: 10.1097/IAE.0000000000001241; PUBMED: 27529839] ">Zhang 2016</a>, and secondary outcomes were not provided in the study protocol of <a href="./references#CD009734-bbs2-0004" title="LeporeD , QuinnGE , MolleF , BaldascinoA , OraziL , SammartinoM , et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology2014;121(11):2212‐9. [PUBMED: 25001158] ">Lepore 2014</a>. </p> </section> <section id="CD009734-sec-0064"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD009734-bbs2-0004" title="LeporeD , QuinnGE , MolleF , BaldascinoA , OraziL , SammartinoM , et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology2014;121(11):2212‐9. [PUBMED: 25001158] ">Lepore 2014</a> and <a href="./references#CD009734-bbs2-0005" title="O'KeeffeN , MurphyJ , O'KeefeM , LaniganB . Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up. Irish Medical Journal2016;109(2):355. [PUBMED: 27685689] ">O'Keeffe 2016</a> randomised the eyes of enrolled infants. If there was significant systemic absorption of bevacizumab, the eye randomised to the control group would have been exposed to both the anti‐VEGF agent and control treatment, resulting in better outcomes in that eye. </p> <p>We intended to assess the likelihood of potential publication bias using funnel plots, provided there were at least 8 to 10 trials (<a href="./references#CD009734-bbs2-0048" title="SterneJAC , EggerM , MoherD (editors) . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Sterne 2011</a>). </p> </section> </section> <section id="CD009734-sec-0065"> <h3 class="title" id="CD009734-sec-0065">Effects of interventions</h3> <p>See: <a href="./full#CD009734-tbl-0001"><b>Summary of findings for the main comparison</b> Anti‐vascular endothelial growth factor therapy compared to conventional laser/cryotherapy in preterm infants with type 1 retinopathy of prematurity</a>; <a href="./full#CD009734-tbl-0002"><b>Summary of findings 2</b> Anti‐vascular endothelial growth factor therapy combined with laser/cryotherapy compared to laser/cryotherapy in preterm infants with type 1 retinopathy of prematurity</a> </p> <section id="CD009734-sec-0066"> <h4 class="title">Comparison 1: anti‐VEGF versus cryo/laser therapy ('monotherapy')</h4> <p>Four trials compared IVB with conventional laser therapy (<a href="./references#CD009734-bbs2-0002" title="GeloneckMM , ChuangAZ , ClarkWL , HuntMG , NormanAA , PackwoodEA , et al. BEAT‐ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmology2014;132(11):1327‐33. [PUBMED: 25103848] Mintz‐HittnerHA , KennedyKA , ChuangAZ ,  BEAT‐ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New England Journal of Medicine2011;364(7):603‐15. [PUBMED: 21323540] NCT00622726 . Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT‐ROP). clinicaltrials.gov/ct2/show/NCT00622726 25 February 2008. ">BEAT‐ROP Trial 2011</a>; <a href="./references#CD009734-bbs2-0004" title="LeporeD , QuinnGE , MolleF , BaldascinoA , OraziL , SammartinoM , et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology2014;121(11):2212‐9. [PUBMED: 25001158] ">Lepore 2014</a>; <a href="./references#CD009734-bbs2-0003" title="KarkhanehR , KhodabandeA , Riazi‐EafahaniM , RoohipoorR , GhassemiF , ImaniM , et al. Efficacy of intravitreal bevacizumab for zone‐II retinopathy of prematurity. Acta Ophthalmologica2016;94(6):e417‐20. [DOI: 10.1111/aos.13008; PUBMED: 27009449] ">Karkhaneh 2016</a>; <a href="./references#CD009734-bbs2-0005" title="O'KeeffeN , MurphyJ , O'KeefeM , LaniganB . Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up. Irish Medical Journal2016;109(2):355. [PUBMED: 27685689] ">O'Keeffe 2016</a>), while one trial compared IVR with laser therapy (<a href="./references#CD009734-bbs2-0006" title="ZhangG , YangM , ZengJ , VakrosG , SuK , ChenM , et al. Shenzhen Screening for Retinopathy of Prematurity Cooperative Group. Comparison of intravitreal injection of ranibuzumab versus laser therapy for zone II treatment‐requiring retinopathy of prematurity. Retina 2016 Aug 12 [Epub ahead of print]. [DOI: 10.1097/IAE.0000000000001241; PUBMED: 27529839] ">Zhang 2016</a>). </p> <section id="CD009734-sec-0067"> <h5 class="title">Primary outcomes</h5> <section id="CD009734-sec-0068"> <h6 class="title">Functional outcome: blindness or severe visual impairment at 6 to 12 months of corrected age </h6> <p>None of the studies reported this outcome.</p> </section> <section id="CD009734-sec-0069"> <h6 class="title">Structural outcome: progression to retinal detachment involving the macula (Outcomes 1.1 to 1.2) </h6> <p>Of the four trials that reported this outcome (<a href="./references#CD009734-bbs2-0002" title="GeloneckMM , ChuangAZ , ClarkWL , HuntMG , NormanAA , PackwoodEA , et al. BEAT‐ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmology2014;132(11):1327‐33. [PUBMED: 25103848] Mintz‐HittnerHA , KennedyKA , ChuangAZ ,  BEAT‐ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New England Journal of Medicine2011;364(7):603‐15. [PUBMED: 21323540] NCT00622726 . Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT‐ROP). clinicaltrials.gov/ct2/show/NCT00622726 25 February 2008. ">BEAT‐ROP Trial 2011</a>; <a href="./references#CD009734-bbs2-0004" title="LeporeD , QuinnGE , MolleF , BaldascinoA , OraziL , SammartinoM , et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology2014;121(11):2212‐9. [PUBMED: 25001158] ">Lepore 2014</a>; <a href="./references#CD009734-bbs2-0003" title="KarkhanehR , KhodabandeA , Riazi‐EafahaniM , RoohipoorR , GhassemiF , ImaniM , et al. Efficacy of intravitreal bevacizumab for zone‐II retinopathy of prematurity. Acta Ophthalmologica2016;94(6):e417‐20. [DOI: 10.1111/aos.13008; PUBMED: 27009449] ">Karkhaneh 2016</a>; <a href="./references#CD009734-bbs2-0006" title="ZhangG , YangM , ZengJ , VakrosG , SuK , ChenM , et al. Shenzhen Screening for Retinopathy of Prematurity Cooperative Group. Comparison of intravitreal injection of ranibuzumab versus laser therapy for zone II treatment‐requiring retinopathy of prematurity. Retina 2016 Aug 12 [Epub ahead of print]. [DOI: 10.1097/IAE.0000000000001241; PUBMED: 27529839] ">Zhang 2016</a>), two reported no cases of retinal detachment in either of the two groups (<a href="./references#CD009734-bbs2-0003" title="KarkhanehR , KhodabandeA , Riazi‐EafahaniM , RoohipoorR , GhassemiF , ImaniM , et al. Efficacy of intravitreal bevacizumab for zone‐II retinopathy of prematurity. Acta Ophthalmologica2016;94(6):e417‐20. [DOI: 10.1111/aos.13008; PUBMED: 27009449] ">Karkhaneh 2016</a>; <a href="./references#CD009734-bbs2-0006" title="ZhangG , YangM , ZengJ , VakrosG , SuK , ChenM , et al. Shenzhen Screening for Retinopathy of Prematurity Cooperative Group. Comparison of intravitreal injection of ranibuzumab versus laser therapy for zone II treatment‐requiring retinopathy of prematurity. Retina 2016 Aug 12 [Epub ahead of print]. [DOI: 10.1097/IAE.0000000000001241; PUBMED: 27529839] ">Zhang 2016</a>). <a href="./references#CD009734-bbs2-0002" title="GeloneckMM , ChuangAZ , ClarkWL , HuntMG , NormanAA , PackwoodEA , et al. BEAT‐ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmology2014;132(11):1327‐33. [PUBMED: 25103848] Mintz‐HittnerHA , KennedyKA , ChuangAZ ,  BEAT‐ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New England Journal of Medicine2011;364(7):603‐15. [PUBMED: 21323540] NCT00622726 . Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT‐ROP). clinicaltrials.gov/ct2/show/NCT00622726 25 February 2008. ">BEAT‐ROP Trial 2011</a> did not report any difference in the incidence of complete or partial retinal detachment between the two groups (risk ratio (RR) 1.04, 95% confidence interval (CI) 0.21 to 5.13; risk difference (RD) 0.00, 95% CI ‐0.06 to 0.07; <a href="./references#CD009734-fig-0003" title="">Analysis 1.1</a>). Only a small number of infants (two infants each in the two groups) had retinal detachment. We graded the quality of evidence as very low due to the small number of events and the potential risk of detection bias (<a href="./full#CD009734-tbl-0001">summary of findings Table for the main comparison</a>). No separate data were available for the risk of retinal detachment involving only the macula. </p> <p>The fourth trial (<a href="./references#CD009734-bbs2-0004" title="LeporeD , QuinnGE , MolleF , BaldascinoA , OraziL , SammartinoM , et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology2014;121(11):2212‐9. [PUBMED: 25001158] ">Lepore 2014</a>), which randomised eyes of the enrolled infants, reported progression to complete retinal detachment four weeks after treatment in one eye (8.5%) treated with conventional laser therapy; none of the eyes randomised to IVB had retinal detachment (RR 0.33, 95% CI 0.01 to 7.50; RD ‐0.08, 95% CI ‐0.27 to 0.11) (<a href="./references#CD009734-fig-0004" title="">Analysis 1.2</a>). </p> </section> </section> <section id="CD009734-sec-0070"> <h5 class="title">Secondary outcomes</h5> <section id="CD009734-sec-0071"> <h6 class="title">Functional outcome(s): refractive error at or after 12 months of age (Outcomes 1.3 to 1.4) </h6> <p>One study reported the outcome using eyes as the denominator (<a href="./references#CD009734-bbs2-0002" title="GeloneckMM , ChuangAZ , ClarkWL , HuntMG , NormanAA , PackwoodEA , et al. BEAT‐ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmology2014;132(11):1327‐33. [PUBMED: 25103848] Mintz‐HittnerHA , KennedyKA , ChuangAZ ,  BEAT‐ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New England Journal of Medicine2011;364(7):603‐15. [PUBMED: 21323540] NCT00622726 . Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT‐ROP). clinicaltrials.gov/ct2/show/NCT00622726 25 February 2008. ">BEAT‐ROP Trial 2011</a>). The risk of very high myopia, defined as ‐8 dioptres (D) or more, at 30 months of age was significantly lower in the eyes of infants randomised to IVB (RR 0.06, 95% CI 0.02 to 0.20; RD ‐0.40, 95% CI ‐0.50 to ‐0.30) (<a href="./references#CD009734-fig-0005" title="">Analysis 1.3</a>). The magnitude of benefit was almost the same in both zone I and zone II posterior ROP. We graded the quality of evidence as low due to the unit of analysis error and risk of detection bias (<a href="./full#CD009734-tbl-0001">summary of findings Table for the main comparison</a>). The mean spherical equivalent refractive error at 30 months of age was also significantly less in the eyes of infants who received IVB (mean difference (MD) 5.68 D, 95% CI 4.33 to 7.02) (<a href="./references#CD009734-bbs2-0002" title="GeloneckMM , ChuangAZ , ClarkWL , HuntMG , NormanAA , PackwoodEA , et al. BEAT‐ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmology2014;132(11):1327‐33. [PUBMED: 25103848] Mintz‐HittnerHA , KennedyKA , ChuangAZ ,  BEAT‐ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New England Journal of Medicine2011;364(7):603‐15. [PUBMED: 21323540] NCT00622726 . Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT‐ROP). clinicaltrials.gov/ct2/show/NCT00622726 25 February 2008. ">BEAT‐ROP Trial 2011</a>). The magnitude of difference was almost the same in both zone I (MD 6.93 D, 95% CI 4.26 to 9.60) and zone II posterior ROP (MD 5.25 D, 95% CI 3.69 to 6.81) (<a href="./references#CD009734-fig-0006" title="">Analysis 1.4</a>). </p> <p>Another study reported no difference in refractive error between the bevacizumab‐treated and laser‐treated eyes at one‐year follow‐up (<a href="./references#CD009734-bbs2-0005" title="O'KeeffeN , MurphyJ , O'KeefeM , LaniganB . Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up. Irish Medical Journal2016;109(2):355. [PUBMED: 27685689] ">O'Keeffe 2016</a>). However, the study allowed cross‐over retreatment (i.e. laser therapy for eyes randomised to bevacizumab and vice versa) in infants with recurrence of ROP, which makes it difficult to ascertain the true effect of the initial intervention. Moreover, the study did not provide relevant data to include the results in the pooled analysis. </p> </section> <section id="CD009734-sec-0072"> <h6 class="title">Unfavourable structural outcomes, assessed at 6 to 12 months of corrected age</h6> <p>None of the studies reported this outcome.</p> </section> <section id="CD009734-sec-0073"> <h6 class="title">Childhood unfavourable visual acuity, assessed at four to six years</h6> <p>One study reported significant myopic shift in the eyes treated with diode laser compared to the eyes that received IVB at five‐year follow‐up (<a href="./references#CD009734-bbs2-0005" title="O'KeeffeN , MurphyJ , O'KeefeM , LaniganB . Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up. Irish Medical Journal2016;109(2):355. [PUBMED: 27685689] ">O'Keeffe 2016</a>). However, the study did not provide relevant data to estimate the risk ratio and its 95% confidence interval. Again, the study allowed cross‐over retreatment in infants with recurrent ROP. </p> </section> <section id="CD009734-sec-0074"> <h6 class="title">Mortality before discharge from the primary hospital and at 30 months of age (Outcomes 1.5 to 1.6) </h6> <p><a href="./references#CD009734-bbs2-0002" title="GeloneckMM , ChuangAZ , ClarkWL , HuntMG , NormanAA , PackwoodEA , et al. BEAT‐ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmology2014;132(11):1327‐33. [PUBMED: 25103848] Mintz‐HittnerHA , KennedyKA , ChuangAZ ,  BEAT‐ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New England Journal of Medicine2011;364(7):603‐15. [PUBMED: 21323540] NCT00622726 . Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT‐ROP). clinicaltrials.gov/ct2/show/NCT00622726 25 February 2008. ">BEAT‐ROP Trial 2011</a> reported no difference in the risk of mortality between the two groups, either before discharge from the primary hospital (RR 1.50, 95% CI 0.26 to 8.75; <a href="./references#CD009734-fig-0007" title="">Analysis 1.5</a>) or at a mean age of 30 months (RR 0.86, 95% CI 0.30 to 2.45; <a href="./references#CD009734-fig-0008" title="">Analysis 1.6</a>). However, the number of events was very small. Another study reported no deaths in either group until discharge from the hospital or until 90 weeks' postmenstrual age (<a href="./references#CD009734-bbs2-0003" title="KarkhanehR , KhodabandeA , Riazi‐EafahaniM , RoohipoorR , GhassemiF , ImaniM , et al. Efficacy of intravitreal bevacizumab for zone‐II retinopathy of prematurity. Acta Ophthalmologica2016;94(6):e417‐20. [DOI: 10.1111/aos.13008; PUBMED: 27009449] ">Karkhaneh 2016</a>). </p> </section> <section id="CD009734-sec-0075"> <h6 class="title">Adverse neurodevelopmental outcomes at 18 to 24 months of corrected age</h6> <p>None of the four studies that randomised infants to the two groups reported this outcome. One study that randomised eyes of the infants to the two groups reported no adverse changes attributable to bevacizumab therapy in magnetic resonance imaging (MRI) at one year of age (<a href="./references#CD009734-bbs2-0005" title="O'KeeffeN , MurphyJ , O'KeefeM , LaniganB . Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up. Irish Medical Journal2016;109(2):355. [PUBMED: 27685689] ">O'Keeffe 2016</a>). </p> </section> <section id="CD009734-sec-0076"> <h6 class="title">Local adverse effects (Outcomes 1.7 to 1.10)</h6> <section id="CD009734-sec-0077"> <p><b>Corneal opacity</b></p> <p>One study reported this outcome using eyes as the denominator (<a href="./references#CD009734-bbs2-0002" title="GeloneckMM , ChuangAZ , ClarkWL , HuntMG , NormanAA , PackwoodEA , et al. BEAT‐ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmology2014;132(11):1327‐33. [PUBMED: 25103848] Mintz‐HittnerHA , KennedyKA , ChuangAZ ,  BEAT‐ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New England Journal of Medicine2011;364(7):603‐15. [PUBMED: 21323540] NCT00622726 . Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT‐ROP). clinicaltrials.gov/ct2/show/NCT00622726 25 February 2008. ">BEAT‐ROP Trial 2011</a>). There was no significant difference in the incidence of corneal opacity requiring corneal transplant between the two groups (RR 0.34, 95% CI 0.01 to 8.26) (<a href="./references#CD009734-fig-0009" title="">Analysis 1.7</a>). </p> </section> <section id="CD009734-sec-0078"> <p><b>Lens opacity</b></p> <p>Three studies reported this outcome using eyes as the denominator (<a href="./references#CD009734-bbs2-0002" title="GeloneckMM , ChuangAZ , ClarkWL , HuntMG , NormanAA , PackwoodEA , et al. BEAT‐ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmology2014;132(11):1327‐33. [PUBMED: 25103848] Mintz‐HittnerHA , KennedyKA , ChuangAZ ,  BEAT‐ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New England Journal of Medicine2011;364(7):603‐15. [PUBMED: 21323540] NCT00622726 . Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT‐ROP). clinicaltrials.gov/ct2/show/NCT00622726 25 February 2008. ">BEAT‐ROP Trial 2011</a>; <a href="./references#CD009734-bbs2-0003" title="KarkhanehR , KhodabandeA , Riazi‐EafahaniM , RoohipoorR , GhassemiF , ImaniM , et al. Efficacy of intravitreal bevacizumab for zone‐II retinopathy of prematurity. Acta Ophthalmologica2016;94(6):e417‐20. [DOI: 10.1111/aos.13008; PUBMED: 27009449] ">Karkhaneh 2016</a>; <a href="./references#CD009734-bbs2-0006" title="ZhangG , YangM , ZengJ , VakrosG , SuK , ChenM , et al. Shenzhen Screening for Retinopathy of Prematurity Cooperative Group. Comparison of intravitreal injection of ranibuzumab versus laser therapy for zone II treatment‐requiring retinopathy of prematurity. Retina 2016 Aug 12 [Epub ahead of print]. [DOI: 10.1097/IAE.0000000000001241; PUBMED: 27529839] ">Zhang 2016</a>). Of these, two studies did not report any case of cataract in either of the groups (<a href="./references#CD009734-bbs2-0003" title="KarkhanehR , KhodabandeA , Riazi‐EafahaniM , RoohipoorR , GhassemiF , ImaniM , et al. Efficacy of intravitreal bevacizumab for zone‐II retinopathy of prematurity. Acta Ophthalmologica2016;94(6):e417‐20. [DOI: 10.1111/aos.13008; PUBMED: 27009449] ">Karkhaneh 2016</a>; <a href="./references#CD009734-bbs2-0006" title="ZhangG , YangM , ZengJ , VakrosG , SuK , ChenM , et al. Shenzhen Screening for Retinopathy of Prematurity Cooperative Group. Comparison of intravitreal injection of ranibuzumab versus laser therapy for zone II treatment‐requiring retinopathy of prematurity. Retina 2016 Aug 12 [Epub ahead of print]. [DOI: 10.1097/IAE.0000000000001241; PUBMED: 27529839] ">Zhang 2016</a>). The third study did not find any significant difference in the incidence of lens opacity requiring cataract removal between the two groups (RR 0.15, 95% CI 0.01 to 2.79) (<a href="./references#CD009734-fig-0010" title="">Analysis 1.8</a>) (<a href="./references#CD009734-bbs2-0002" title="GeloneckMM , ChuangAZ , ClarkWL , HuntMG , NormanAA , PackwoodEA , et al. BEAT‐ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmology2014;132(11):1327‐33. [PUBMED: 25103848] Mintz‐HittnerHA , KennedyKA , ChuangAZ ,  BEAT‐ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New England Journal of Medicine2011;364(7):603‐15. [PUBMED: 21323540] NCT00622726 . Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT‐ROP). clinicaltrials.gov/ct2/show/NCT00622726 25 February 2008. ">BEAT‐ROP Trial 2011</a>). </p> </section> <section id="CD009734-sec-0079"> <p><b>Endophthalmitis and vitreous haemorrhage</b></p> <p>The two studies that reported this outcome did not find any case of endophthalmitis (<a href="./references#CD009734-fig-0011" title="">Analysis 1.9</a>) or vitreous haemorrhage (<a href="./references#CD009734-fig-0012" title="">Analysis 1.10</a>) in infants randomised to bevacizumab/ranibizumab or in those randomised to laser therapy (<a href="./references#CD009734-bbs2-0003" title="KarkhanehR , KhodabandeA , Riazi‐EafahaniM , RoohipoorR , GhassemiF , ImaniM , et al. Efficacy of intravitreal bevacizumab for zone‐II retinopathy of prematurity. Acta Ophthalmologica2016;94(6):e417‐20. [DOI: 10.1111/aos.13008; PUBMED: 27009449] ">Karkhaneh 2016</a>; <a href="./references#CD009734-bbs2-0006" title="ZhangG , YangM , ZengJ , VakrosG , SuK , ChenM , et al. Shenzhen Screening for Retinopathy of Prematurity Cooperative Group. Comparison of intravitreal injection of ranibuzumab versus laser therapy for zone II treatment‐requiring retinopathy of prematurity. Retina 2016 Aug 12 [Epub ahead of print]. [DOI: 10.1097/IAE.0000000000001241; PUBMED: 27529839] ">Zhang 2016</a>). </p> </section> <section id="CD009734-sec-0080"> <p><b>Choroidal ischaemia/rupture</b></p> <p>None of the studies reported this outcome.</p> </section> </section> <section id="CD009734-sec-0081"> <h6 class="title">Acute systemic effects during or immediately after the treatment procedure</h6> <p>None of the studies reported this outcome.</p> </section> <section id="CD009734-sec-0082"> <h6 class="title">Delayed systemic effects</h6> <p>One study that randomised eyes of the infants to the two groups reported no evidence of systemic adverse effects associated with bevacizumab at five‐year follow‐up (<a href="./references#CD009734-bbs2-0005" title="O'KeeffeN , MurphyJ , O'KeefeM , LaniganB . Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up. Irish Medical Journal2016;109(2):355. [PUBMED: 27685689] ">O'Keeffe 2016</a>). None of the other studies reported this outcome. </p> </section> <section id="CD009734-sec-0083"> <h6 class="title">Parental satisfaction regarding the treatment (in Likert or other such scales)</h6> <p>None of the studies reported this outcome.</p> </section> <section id="CD009734-sec-0084"> <h6 class="title">Recurrence of ROP (Outcomes 1.11 to 1.12)</h6> <p>A total of four studies reported this outcome (<a href="./references#CD009734-bbs2-0002" title="GeloneckMM , ChuangAZ , ClarkWL , HuntMG , NormanAA , PackwoodEA , et al. BEAT‐ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmology2014;132(11):1327‐33. [PUBMED: 25103848] Mintz‐HittnerHA , KennedyKA , ChuangAZ ,  BEAT‐ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New England Journal of Medicine2011;364(7):603‐15. [PUBMED: 21323540] NCT00622726 . Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT‐ROP). clinicaltrials.gov/ct2/show/NCT00622726 25 February 2008. ">BEAT‐ROP Trial 2011</a>; <a href="./references#CD009734-bbs2-0003" title="KarkhanehR , KhodabandeA , Riazi‐EafahaniM , RoohipoorR , GhassemiF , ImaniM , et al. Efficacy of intravitreal bevacizumab for zone‐II retinopathy of prematurity. Acta Ophthalmologica2016;94(6):e417‐20. [DOI: 10.1111/aos.13008; PUBMED: 27009449] ">Karkhaneh 2016</a>; <a href="./references#CD009734-bbs2-0005" title="O'KeeffeN , MurphyJ , O'KeefeM , LaniganB . Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up. Irish Medical Journal2016;109(2):355. [PUBMED: 27685689] ">O'Keeffe 2016</a>; <a href="./references#CD009734-bbs2-0006" title="ZhangG , YangM , ZengJ , VakrosG , SuK , ChenM , et al. Shenzhen Screening for Retinopathy of Prematurity Cooperative Group. Comparison of intravitreal injection of ranibuzumab versus laser therapy for zone II treatment‐requiring retinopathy of prematurity. Retina 2016 Aug 12 [Epub ahead of print]. [DOI: 10.1097/IAE.0000000000001241; PUBMED: 27529839] ">Zhang 2016</a>). Pooled analysis revealed no significant difference in the risk of recurrence of ROP requiring retreatment up to six months of age in infants randomised to IVB or IVR and those who received conventional laser therapy (RR 0.88, 95% CI 0.47 to 1.63; RD ‐0.02, 95% CI ‐0.12 to 0.07; 2 studies; fixed‐effect model) (<a href="./references#CD009734-fig-0013" title="">Analysis 1.11</a>). We graded the quality of evidence for this outcome as very low (<a href="./full#CD009734-tbl-0001">summary of findings Table for the main comparison</a>). There was large heterogeneity (I<sup>2</sup> = 86%), which was essentially due to the differences in the direction of effect between infants with zone I and those with zone II ROP (subgroup analysis); while there was a significant reduction in the risk of recurrence in infants with zone I ROP (RR 0.15, 95% CI 0.04 to 0.62), the risk of recurrence was significantly higher in infants with zone II ROP who received bevacizumab/ranibizumab monotherapy (RR 2.53, 95% CI 1.01 to 6.32) (<a href="./references#CD009734-fig-0013" title="">Analysis 1.11</a>). </p> <p>Pooled analysis of the other two studies, which reported eye‐level outcomes (not infant‐level outcomes), revealed significant increase in the risk of recurrence of ROP in the eyes that received bevacizumab therapy (RR 5.36, 95% CI 1.22 to 23.50) (<a href="./references#CD009734-bbs2-0003" title="KarkhanehR , KhodabandeA , Riazi‐EafahaniM , RoohipoorR , GhassemiF , ImaniM , et al. Efficacy of intravitreal bevacizumab for zone‐II retinopathy of prematurity. Acta Ophthalmologica2016;94(6):e417‐20. [DOI: 10.1111/aos.13008; PUBMED: 27009449] ">Karkhaneh 2016</a>; <a href="./references#CD009734-bbs2-0005" title="O'KeeffeN , MurphyJ , O'KeefeM , LaniganB . Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up. Irish Medical Journal2016;109(2):355. [PUBMED: 27685689] ">O'Keeffe 2016</a>). Of these two studies, <a href="./references#CD009734-bbs2-0005" title="O'KeeffeN , MurphyJ , O'KeefeM , LaniganB . Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up. Irish Medical Journal2016;109(2):355. [PUBMED: 27685689] ">O'Keeffe 2016</a> enrolled infants with zone I or II ROP, while <a href="./references#CD009734-bbs2-0003" title="KarkhanehR , KhodabandeA , Riazi‐EafahaniM , RoohipoorR , GhassemiF , ImaniM , et al. Efficacy of intravitreal bevacizumab for zone‐II retinopathy of prematurity. Acta Ophthalmologica2016;94(6):e417‐20. [DOI: 10.1111/aos.13008; PUBMED: 27009449] ">Karkhaneh 2016</a> enrolled infants with only zone II ROP (<a href="./references#CD009734-fig-0014" title="">Analysis 1.12</a>). </p> </section> </section> </section> <section id="CD009734-sec-0085"> <h4 class="title">Comparison 2: anti‐VEGF plus cryo/laser therapy ('combination therapy') versus cryo/laser therapy alone </h4> <p><a href="./references#CD009734-bbs2-0001" title="AutrataR , KrejčířováI , ŠenkováK , HoloušováM , DoleželZ , BorekI . Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. European Journal of Ophthalmology2012;22(5):687‐94. [PUBMED: 22669848] ">Autrata 2012</a> compared intravitreal pegaptanib plus conventional laser therapy with laser and cryotherapy in preterm infants with stage 3+ ROP. </p> <section id="CD009734-sec-0086"> <h5 class="title">Primary outcomes</h5> <section id="CD009734-sec-0087"> <h6 class="title">Functional outcome: blindness or severe visual impairment at 6 to 12 months of corrected age </h6> <p>The study did not report this outcome.</p> </section> <section id="CD009734-sec-0088"> <h6 class="title">Structural outcome: progression to retinal detachment involving the macula (Outcome 2.1) </h6> <p>The study reported the outcome using eyes as the denominator. The risk of complete or partial retinal detachment was significantly lower in the eyes of infants randomised to intravitreal pegaptanib plus laser therapy (RR 0.26, 95% CI 0.12 to 0.55; RD ‐0.29, 95% CI ‐0.42 to ‐0.16; 1 study; 152 infants) (<a href="./references#CD009734-fig-0015" title="">Analysis 2.1</a>). We graded the quality of evidence as low due to the unit of analysis error and risk of detection bias (<a href="./full#CD009734-tbl-0002">summary of findings Table 2</a>). </p> <p>No separate data were available for the risk of retinal detachment involving only the macula. </p> </section> </section> <section id="CD009734-sec-0089"> <h5 class="title">Secondary outcomes</h5> <section id="CD009734-sec-0090"> <h6 class="title">Functional outcome(s): refractive error at 6 to 12 months of age or later</h6> <p>The study did not report this outcome.</p> </section> <section id="CD009734-sec-0091"> <h6 class="title">Unfavourable structural outcomes at 6 to 12 months of age</h6> <p>The study did not report this outcome.</p> </section> <section id="CD009734-sec-0092"> <h6 class="title">Childhood unfavourable visual acuity</h6> <p>The study did not report this outcome.</p> </section> <section id="CD009734-sec-0093"> <h6 class="title">Mortality before discharge from the primary hospital and at 30 months of age</h6> <p>The study did not report this outcome.</p> </section> <section id="CD009734-sec-0094"> <h6 class="title">Adverse neurodevelopmental outcomes at 18 to 24 months of corrected age</h6> <p>The study did not report this outcome.</p> </section> <section id="CD009734-sec-0095"> <h6 class="title">Local adverse effects (Outcomes 2.2)</h6> <p>The study reported the outcome using eyes as the denominator. There was no significant difference in the risk of perioperative retinal haemorrhages after laser therapy between the two groups (RR 0.62, 95% CI 0.24 to 1.56; 1 study; 152 infants) (<a href="./references#CD009734-fig-0016" title="">Analysis 2.2</a>). The study did not report the risk of conjunctival haemorrhage or vitreous haemorrhage in the two groups. </p> <p>The study reported that "no systemic or significant ocular complications of intravitreal pegaptanib injections, such as endophthalmitis or RD were found during the follow‐up period after treatment", but did not provide the corresponding data for the other group. </p> </section> <section id="CD009734-sec-0096"> <h6 class="title">Acute systemic effects during or immediately after the treatment procedure</h6> <p>The study did not report this outcome (see 'Local adverse effects' above).</p> </section> <section id="CD009734-sec-0097"> <h6 class="title">Delayed systemic effects</h6> <p>The study did not report this outcome.</p> </section> <section id="CD009734-sec-0098"> <h6 class="title">Parental satisfaction regarding the treatment (in Likert or other such scales)</h6> <p>The study did not report this outcome.</p> </section> <section id="CD009734-sec-0099"> <h6 class="title">Recurrence of ROP (Outcome 2.3)</h6> <p>Infants randomised to intravitreal pegaptanib plus laser therapy had a significantly lower risk of recurrence of ROP by 55 weeks' postmenstrual age compared to those randomised to laser therapy with cryotherapy (RR 0.29, 95% CI 0.12 to 0.70; RD ‐0.35, 95% CI ‐0.55 to ‐0.16; number needed to treat for an additional beneficial outcome 3, 95% CI 2 to 6; 1 study; 76 infants) (<a href="./references#CD009734-fig-0017" title="">Analysis 2.3</a>). We graded the quality of evidence for this outcome as low due to the risk of detection bias and unclear risk of selection bias (<a href="./full#CD009734-tbl-0002">summary of findings Table 2</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009734-sec-0100" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009734-sec-0100"></div> <section id="CD009734-sec-0101"> <h3 class="title" id="CD009734-sec-0101">Summary of main results</h3> <p>The systematic review included six randomised trials, of which five evaluated the effects of bevacizumab/ranibizumab monotherapy, while the sixth one examined the effects of intravitreal pegaptanib plus laser therapy. When used as monotherapy, IVB/IVR did not improve short‐term structural outcomes (partial or complete retinal detachment and recurrence of ROP) but significantly reduced the risk of refractive errors at 30 months of age. When used in conjunction with laser therapy, intravitreal pegaptanib reduced the risk of retinal detachment as well as recurrence of ROP in infants with stage 3+ ROP. We noted no significant difference in the incidence of local adverse events with any of the drugs. However, the quality of evidence was very low to low for most outcomes due to the risk of detection bias and other biases. </p> <p>On subgroup analysis, we found the risk of recurrence of ROP requiring retreatment to be different in infants with zone I ROP and those with zone II ROP receiving IVB/IVR monotherapy: while the risk was reduced in infants with zone I ROP, we found it to be significantly higher in those with zone II ROP. However, the numbers were too small to draw any meaningful conclusion on this subgroup analysis. </p> </section> <section id="CD009734-sec-0102"> <h3 class="title" id="CD009734-sec-0102">Overall completeness and applicability of evidence</h3> <p>The updated evidence remains incomplete for three major reasons. The first reason is the limited number of studies included in the review. Despite the well‐established pathophysiological rationale for using anti‐VEGF agents and the short‐term benefits observed in numerous case reports, case series, and non‐randomised studies (<a href="./references#CD009734-bbs2-0046" title="ShahPK , NarendranV , TawansyKA , RaghuramA , NarendranK . Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian Journal of Ophthalmology2007;55(1):75‐6. [PUBMED: 17189897] ">Shah 2007</a>; <a href="./references#CD009734-bbs2-0035" title="KongL , Mintz‐HittnerHA , PenlandRL , KretzerFL , Chevez‐BarriosP . Intravitreous bevacizumab as anti‐vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Archives of Ophthalmology2008;126(8):1161‐3. [PUBMED: 18695118] ">Kong 2008</a>; <a href="./references#CD009734-bbs2-0040" title="Mintz‐HittnerHA , KuffelRRJr . Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina2008;28(6):831‐8. [PUBMED: 18536599] ">Mintz‐Hittner 2008</a>; <a href="./references#CD009734-bbs2-0051" title="WuWC , KuoHK , YehPT , YangCM , LaiCC , ChenSN . An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan. American Journal of Ophthalmology2013;155(1):150‐8. [PUBMED: 22967867] ">Wu 2013</a>; <a href="./references#CD009734-bbs2-0041" title="NicoarăSD , ȘtefănuţAC , NascutzyC , ZaharieGC , ToaderLE , DruganTC . Regression rates following the treatment of aggressive posterior retinopathy of prematurity with bevacizumab versus laser: 8‐year retrospective analysis. Medical Science Monitor2016;22:1192‐209. [PUBMED: 27062023] ">Nicoara 2016</a>), only six randomised controlled trials enrolling 383 infants have been published so far. Consequently, the short‐term benefits observed with anti‐VEGF agents in the observational studies could be neither confirmed nor refuted with enough confidence in the current review. Secondly, the long‐term beneficial effects, if any, in terms of favourable structural and functional outcomes are not yet known. Though IVB monotherapy has been shown to reduce the risk of refractive errors (very high myopia) at 30 months of age, the effects of the intervention on other long‐term outcomes are largely unknown. Thirdly, the safety concerns of anti‐VEGF drugs have yet to be addressed. One trial reported no difference in the risk of mortality between intervention and control groups at a mean age of 30 months (<a href="./references#CD009734-bbs2-0002" title="GeloneckMM , ChuangAZ , ClarkWL , HuntMG , NormanAA , PackwoodEA , et al. BEAT‐ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmology2014;132(11):1327‐33. [PUBMED: 25103848] Mintz‐HittnerHA , KennedyKA , ChuangAZ ,  BEAT‐ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New England Journal of Medicine2011;364(7):603‐15. [PUBMED: 21323540] NCT00622726 . Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT‐ROP). clinicaltrials.gov/ct2/show/NCT00622726 25 February 2008. ">BEAT‐ROP Trial 2011</a>), but the number of events was very small. Another trial that randomised eyes of the infants to the two groups reported no evidence of abnormal MRI findings or systemic adverse effects attributable to bevacizumab therapy at one and five years of follow‐up, respectively (<a href="./references#CD009734-bbs2-0005" title="O'KeeffeN , MurphyJ , O'KeefeM , LaniganB . Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up. Irish Medical Journal2016;109(2):355. [PUBMED: 27685689] ">O'Keeffe 2016</a>). Given the potential risk of systemic absorption and consequent adverse effects like cerebrovascular accidents following intravitreal anti‐VEGF therapy, the lack of evidence on safety outcomes is a major concern. A recently published study that used the data from the Canadian Neonatal Network demonstrated 3.1 times higher odds (95% CI 1.2 to 8.4) of severe neurodevelopmental disabilities in preterm infants born before 29 weeks' gestation and treated with bevacizumab, after adjusting for key confounders like gestation, gender, maternal education, Score for Neonatal Acute Physiology‐II (SNAP‐II) score, bronchopulmonary dysplasia, sepsis, and severe brain injury (<a href="./references#CD009734-bbs2-0016" title="MorinJ , LuuTM , SupersteinR , OspinaLH , LefebvreF , SimardMN , et al. Canadian Neonatal Network and the Canadian Neonatal Follow‐Up Network Investigators. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics2016;137(4):e20153218. [DOI: 10.1542/peds.2015‐3218; PUBMED: 27244705] ">Morin 2016</a>). These findings further underscore the importance of evaluating long‐term safety outcomes of anti‐VEGF therapy . </p> <p>The incomplete evidence indeed limits our ability to identify a simple, safe, and effective therapy for ROP. Unlike the current standard of treatment, laser therapy, anti‐VEGF administration is technically simple and does not require general anaesthesia or the services of a skilled retinal surgeon. This could be a great boon, particularly in settings with limited resources in low‐ and middle‐income countries. There is an urgent need to generate more evidence on the long‐term structural outcomes as well as the adverse effects following intravitreal therapy with anti‐VEGF agents before they can be considered for routine clinical use in infants with ROP. Future studies should also examine how these drugs affect the natural history of the disease, the focus being late recurrence that might warrant repeat doses of the drug, long‐term follow‐up, and the risk of local complications like infections following therapy, especially in resource‐restricted settings. </p> </section> <section id="CD009734-sec-0103"> <h3 class="title" id="CD009734-sec-0103">Quality of the evidence</h3> <p>We intended to include all primary and secondary outcomes of the review in the 'Summary of findings' tables. However, many of the outcomes were not reported in the included studies. We therefore reported only nine outcomes for the comparison of 'anti‐VEGF versus cryo/laser therapy' and three outcomes for the comparison of 'anti‐VEGF plus cryo/laser therapy versus cryo/laser therapy alone' in the 'Summary of findings' tables. </p> <p>We graded the quality of evidence as very low to low for almost all outcomes (<a href="./full#CD009734-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD009734-tbl-0002">summary of findings Table 2</a>). The risk of detection bias was high in all of the studies because the outcome assessors were not masked to the group allocation. The risk of other biases, including selection and reporting bias, was low in <a href="./references#CD009734-bbs2-0002" title="GeloneckMM , ChuangAZ , ClarkWL , HuntMG , NormanAA , PackwoodEA , et al. BEAT‐ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmology2014;132(11):1327‐33. [PUBMED: 25103848] Mintz‐HittnerHA , KennedyKA , ChuangAZ ,  BEAT‐ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New England Journal of Medicine2011;364(7):603‐15. [PUBMED: 21323540] NCT00622726 . Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT‐ROP). clinicaltrials.gov/ct2/show/NCT00622726 25 February 2008. ">BEAT‐ROP Trial 2011</a>, and unclear in the other studies (<a href="./references#CD009734-bbs2-0001" title="AutrataR , KrejčířováI , ŠenkováK , HoloušováM , DoleželZ , BorekI . Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. European Journal of Ophthalmology2012;22(5):687‐94. [PUBMED: 22669848] ">Autrata 2012</a>; <a href="./references#CD009734-bbs2-0004" title="LeporeD , QuinnGE , MolleF , BaldascinoA , OraziL , SammartinoM , et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology2014;121(11):2212‐9. [PUBMED: 25001158] ">Lepore 2014</a>; <a href="./references#CD009734-bbs2-0003" title="KarkhanehR , KhodabandeA , Riazi‐EafahaniM , RoohipoorR , GhassemiF , ImaniM , et al. Efficacy of intravitreal bevacizumab for zone‐II retinopathy of prematurity. Acta Ophthalmologica2016;94(6):e417‐20. [DOI: 10.1111/aos.13008; PUBMED: 27009449] ">Karkhaneh 2016</a>; <a href="./references#CD009734-bbs2-0005" title="O'KeeffeN , MurphyJ , O'KeefeM , LaniganB . Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up. Irish Medical Journal2016;109(2):355. [PUBMED: 27685689] ">O'Keeffe 2016</a>; <a href="./references#CD009734-bbs2-0006" title="ZhangG , YangM , ZengJ , VakrosG , SuK , ChenM , et al. Shenzhen Screening for Retinopathy of Prematurity Cooperative Group. Comparison of intravitreal injection of ranibuzumab versus laser therapy for zone II treatment‐requiring retinopathy of prematurity. Retina 2016 Aug 12 [Epub ahead of print]. [DOI: 10.1097/IAE.0000000000001241; PUBMED: 27529839] ">Zhang 2016</a>). </p> </section> <section id="CD009734-sec-0104"> <h3 class="title" id="CD009734-sec-0104">Potential biases in the review process</h3> <p>Most outcomes of the review were not reported in the included studies. We are contacting the authors of the studies to collect additional information on these outcomes. Also, we did not perform a subgroup analysis based on the specific anti‐VEGF agent used because of the small number of studies (and the small number of infants enrolled in them). </p> </section> <section id="CD009734-sec-0105"> <h3 class="title" id="CD009734-sec-0105">Agreements and disagreements with other studies or reviews</h3> <p>An earlier systematic review, 'Off‐label use of bevacizumab for severe retinopathy of prematurity', was published in 2009 (<a href="./references#CD009734-bbs2-0039" title="MicieliJA , SurkontM , SmithAF . A systematic analysis of the off‐label use of bevacizumab for severe retinopathy of prematurity. American Journal of Ophthalmology2009;148(4):536‐43.e2. [PUBMED: 19660736] ">Micieli 2009</a>). It included nine articles, of which six were case reports, two were retrospective studies, and one was a prospective case series, and found considerable variability in how bevacizumab is used for the treatment of ROP, concluding that "further randomized control trials are warranted". Another systematic review, published in 2015, included 24 studies that evaluated anti‐VEGF therapy in 1457 eyes (<a href="./references#CD009734-bbs2-0043" title="PertlL , SteinwenderG , MayerC , HausbergerS , PöschlE‐M , WackernagelW , et al. A systematic review and meta‐analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity. PLoS ONE2015;10(6):e0129383. ">Pertl 2015</a>). Almost all the studies were observational except for one randomized and two case‐control studies. The review estimated a 6‐month risk of retreatment of 2.8% per eye, and a 6‐month risk of ocular complication without the need of retreatment of 1.6% per eye. Only isolated incidents of systemic complications were reported. The study concluded that "VEGF inhibitors seem to be associated with low recurrence rates and ocular complication rates". </p> <p>The current review included six randomised trials, five on intravitreal bevacizumab/ranibizumab monotherapy and one on intravitreal pegaptanib combination therapy. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009734-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/urn:x-wiley:14651858:media:CD009734:CD009734-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_t/tCD009734-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram: review update." data-id="CD009734-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram: review update.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/full#CD009734-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009734-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/urn:x-wiley:14651858:media:CD009734:CD009734-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_t/tCD009734-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009734-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/full#CD009734-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009734-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/urn:x-wiley:14651858:media:CD009734:CD009734-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_t/tCD009734-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐vascular endothelial growth factor therapy versus cryo/laser therapy, Outcome 1 Structural outcome ‐ partial or complete retinal detachment." data-id="CD009734-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Anti‐vascular endothelial growth factor therapy versus cryo/laser therapy, Outcome 1 Structural outcome ‐ partial or complete retinal detachment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/references#CD009734-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009734-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/urn:x-wiley:14651858:media:CD009734:CD009734-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_t/tCD009734-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐vascular endothelial growth factor therapy versus cryo/laser therapy, Outcome 2 Structural outcome ‐ complete retinal detachment (unit of analysis: eyes)." data-id="CD009734-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Anti‐vascular endothelial growth factor therapy versus cryo/laser therapy, Outcome 2 Structural outcome ‐ complete retinal detachment (unit of analysis: eyes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/references#CD009734-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009734-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/urn:x-wiley:14651858:media:CD009734:CD009734-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_t/tCD009734-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐vascular endothelial growth factor therapy versus cryo/laser therapy, Outcome 3 Refractive error ‐ very high myopia ‐ at or after 12 months of age (unit of analysis: eyes)." data-id="CD009734-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Anti‐vascular endothelial growth factor therapy versus cryo/laser therapy, Outcome 3 Refractive error ‐ very high myopia ‐ at or after 12 months of age (unit of analysis: eyes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/references#CD009734-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009734-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/urn:x-wiley:14651858:media:CD009734:CD009734-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_t/tCD009734-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐vascular endothelial growth factor therapy versus cryo/laser therapy, Outcome 4 Refractive error ‐ spherical equivalent refractions ‐ at 30 months of age (unit of analysis: eyes)." data-id="CD009734-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Anti‐vascular endothelial growth factor therapy versus cryo/laser therapy, Outcome 4 Refractive error ‐ spherical equivalent refractions ‐ at 30 months of age (unit of analysis: eyes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/references#CD009734-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009734-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/urn:x-wiley:14651858:media:CD009734:CD009734-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_t/tCD009734-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐vascular endothelial growth factor therapy versus cryo/laser therapy, Outcome 5 Mortality before discharge from primary hospital." data-id="CD009734-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Anti‐vascular endothelial growth factor therapy versus cryo/laser therapy, Outcome 5 Mortality before discharge from primary hospital. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/references#CD009734-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009734-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/urn:x-wiley:14651858:media:CD009734:CD009734-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_t/tCD009734-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐vascular endothelial growth factor therapy versus cryo/laser therapy, Outcome 6 Mortality at 30 months of age." data-id="CD009734-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Anti‐vascular endothelial growth factor therapy versus cryo/laser therapy, Outcome 6 Mortality at 30 months of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/references#CD009734-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009734-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/urn:x-wiley:14651858:media:CD009734:CD009734-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_t/tCD009734-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐vascular endothelial growth factor therapy versus cryo/laser therapy, Outcome 7 Local adverse effects ‐ corneal opacity requiring corneal transplant (unit of analysis: eyes)." data-id="CD009734-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Anti‐vascular endothelial growth factor therapy versus cryo/laser therapy, Outcome 7 Local adverse effects ‐ corneal opacity requiring corneal transplant (unit of analysis: eyes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/references#CD009734-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009734-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/urn:x-wiley:14651858:media:CD009734:CD009734-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_t/tCD009734-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐vascular endothelial growth factor therapy versus cryo/laser therapy, Outcome 8 Local adverse effects ‐ lens opacity requiring cataract removal (unit of analysis: eyes)." data-id="CD009734-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Anti‐vascular endothelial growth factor therapy versus cryo/laser therapy, Outcome 8 Local adverse effects ‐ lens opacity requiring cataract removal (unit of analysis: eyes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/references#CD009734-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009734-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/urn:x-wiley:14651858:media:CD009734:CD009734-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_t/tCD009734-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐vascular endothelial growth factor therapy versus cryo/laser therapy, Outcome 9 Local adverse effects ‐ endophthalmitis." data-id="CD009734-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Anti‐vascular endothelial growth factor therapy versus cryo/laser therapy, Outcome 9 Local adverse effects ‐ endophthalmitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/references#CD009734-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009734-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/urn:x-wiley:14651858:media:CD009734:CD009734-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_t/tCD009734-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐vascular endothelial growth factor therapy versus cryo/laser therapy, Outcome 10 Local adverse effects ‐ vitreous haemorrhage." data-id="CD009734-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Anti‐vascular endothelial growth factor therapy versus cryo/laser therapy, Outcome 10 Local adverse effects ‐ vitreous haemorrhage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/references#CD009734-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009734-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/urn:x-wiley:14651858:media:CD009734:CD009734-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_t/tCD009734-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐vascular endothelial growth factor therapy versus cryo/laser therapy, Outcome 11 Recurrence of ROP." data-id="CD009734-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Anti‐vascular endothelial growth factor therapy versus cryo/laser therapy, Outcome 11 Recurrence of ROP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/references#CD009734-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009734-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/urn:x-wiley:14651858:media:CD009734:CD009734-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_t/tCD009734-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐vascular endothelial growth factor therapy versus cryo/laser therapy, Outcome 12 Recurrence of ROP (unit of analysis: eyes)." data-id="CD009734-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Anti‐vascular endothelial growth factor therapy versus cryo/laser therapy, Outcome 12 Recurrence of ROP (unit of analysis: eyes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/references#CD009734-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009734-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/urn:x-wiley:14651858:media:CD009734:CD009734-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_t/tCD009734-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Anti‐vascular endothelial growth factor therapy plus cryo/laser therapy versus cryo/laser therapy, Outcome 1 Structural outcome ‐ retinal detachment (unit of analysis: eyes)." data-id="CD009734-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Anti‐vascular endothelial growth factor therapy plus cryo/laser therapy versus cryo/laser therapy, Outcome 1 Structural outcome ‐ retinal detachment (unit of analysis: eyes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/references#CD009734-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009734-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/urn:x-wiley:14651858:media:CD009734:CD009734-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_t/tCD009734-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Anti‐vascular endothelial growth factor therapy plus cryo/laser therapy versus cryo/laser therapy, Outcome 2 Local adverse effects ‐ perioperative retinal haemorrhages (unit of analysis: eyes)." data-id="CD009734-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Anti‐vascular endothelial growth factor therapy plus cryo/laser therapy versus cryo/laser therapy, Outcome 2 Local adverse effects ‐ perioperative retinal haemorrhages (unit of analysis: eyes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/references#CD009734-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009734-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/urn:x-wiley:14651858:media:CD009734:CD009734-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_t/tCD009734-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Anti‐vascular endothelial growth factor therapy plus cryo/laser therapy versus cryo/laser therapy, Outcome 3 Recurrence of ROP by 55 weeks' postmenstrual age." data-id="CD009734-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Anti‐vascular endothelial growth factor therapy plus cryo/laser therapy versus cryo/laser therapy, Outcome 3 Recurrence of ROP by 55 weeks' postmenstrual age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/references#CD009734-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/media/CDSR/CD009734/image_n/nCD009734-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009734-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Anti‐vascular endothelial growth factor therapy compared to conventional laser/cryotherapy in preterm infants with type 1 retinopathy of prematurity</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Anti‐vascular endothelial growth factor (anti‐VEGF) therapy compared to conventional laser/cryotherapy in preterm infants with type 1 retinopathy of prematurity (ROP)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> preterm infants with type 1 ROP<br/> <b>Setting:</b> neonatal units<br/> <b>Intervention:</b> anti‐VEGF therapy<br/> <b>Comparison:</b> conventional laser/cryotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with conventional laser/cryotherapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anti‐VEGF therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Structural outcome ‐ retinal detachment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.04<br/> (0.21 to 5.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>272<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/> (3 to 77) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Structural outcome ‐ complete retinal detachment</b> </p> <p>(unit of analysis: eyes)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33<br/> (0.01 to 7.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>26<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3 4 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<br/> (1 to 577) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Refractive error ‐ very high myopia ‐ at 30 months of age</b> </p> <p>(unit of analysis: eyes)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.06<br/> (0.02 to 0.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>211<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>416 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<br/> (8 to 83) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality before discharge from primary hospital</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.50<br/> (0.26 to 8.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>229<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 3 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000<br/> (5 to 158) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality at 30 months of age</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/> (0.30 to 2.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>150<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 3 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>93 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000<br/> (28 to 229) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Local adverse effects ‐ corneal opacity requiring corneal transplant</b> </p> <p>(unit of analysis: eyes)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.34<br/> (0.01 to 8.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>286<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/> (0 to 57) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Local adverse effects ‐ lens opacity requiring cataract removal</b> </p> <p>(unit of analysis: eyes)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.15<br/> (0.01 to 2.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>544<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/> (0 to 31) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of ROP (up to 6 months of age)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/> (0.47 to 1.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>193<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>204 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 per 1000<br/> (96 to 333) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of ROP</b> </p> <p>(unit of analysis: eyes)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.36<br/> (1.22 to 23.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>188<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>123 per 1000<br/> (28 to 540) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Outcome assessment not masked.<br/> <sup>2</sup>95% CI around the pooled estimate includes both 1) no effect and 2) appreciable benefit or appreciable harm.<br/> <sup>3</sup>Number of events too small.<br/> <sup>4</sup>Serious risk of bias in analysis (unit of analysis error) in one or more of the included studies.<br/> <sup>5</sup>Outcome assessment not masked, but outcome is objective.<br/> <sup>6</sup>Evidence of large heterogeneity (I<sup>2</sup> = 86%).<br/> <sup>7</sup>Unclear risk of selection bias (details of allocation concealment not provided in the individual studies). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Anti‐vascular endothelial growth factor therapy compared to conventional laser/cryotherapy in preterm infants with type 1 retinopathy of prematurity</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/full#CD009734-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009734-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Anti‐vascular endothelial growth factor therapy combined with laser/cryotherapy compared to laser/cryotherapy in preterm infants with type 1 retinopathy of prematurity</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Anti‐vascular endothelial growth factor (anti‐VEGF) therapy combined with laser/cryotherapy compared to laser/cryotherapy in preterm infants with type 1 retinopathy of prematurity (ROP)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> preterm infants with type 1 ROP<br/> <b>Settings:</b> neonatal units<br/> <b>Intervention:</b> anti‐VEGF combined with laser/cryotherapy<br/> <b>Comparison:</b> laser/cryotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes*</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with conventional laser/cryotherapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anti‐VEGF therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Structural outcome ‐ retinal detachment</b> </p> <p>(unit of analysis: eyes)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.26<br/> (0.12 to 0.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>152<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>393 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>102 per 1000<br/> (47 to 216) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Local adverse effects ‐ perioperative retinal haemorrhages</b> </p> <p>(unit of analysis: eyes)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.62<br/> (0.24 to 1.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>152<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1,2,3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 1000<br/> (34 to 223) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of ROP by 55 weeks' postmenstrual age</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.29<br/> (0.12 to 0.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>76<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>145 per 1000<br/> (60 to 350) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*Only the outcomes for which data are available are reported here.</p> <p><sup>#</sup>The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Outcome assessment not masked.<br/> <sup>2</sup>Serious risk of bias in analysis (unit of analysis error).<br/> <sup>3</sup>Unclear risk of selection bias<br/> <sup>4</sup>95% CI around the pooled estimate includes both 1) no effect and 2) appreciable benefit or appreciable harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Anti‐vascular endothelial growth factor therapy combined with laser/cryotherapy compared to laser/cryotherapy in preterm infants with type 1 retinopathy of prematurity</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/full#CD009734-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009734-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anti‐vascular endothelial growth factor therapy versus cryo/laser therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Structural outcome ‐ partial or complete retinal detachment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.21, 5.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Zone I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.01, 4.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Zone II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.13 [0.25, 103.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Structural outcome ‐ complete retinal detachment (unit of analysis: eyes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Refractive error ‐ very high myopia ‐ at or after 12 months of age (unit of analysis: eyes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.02, 0.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Zone I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.02, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Zone II posterior</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.01, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Refractive error ‐ spherical equivalent refractions ‐ at 30 months of age (unit of analysis: eyes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.68 [4.33, 7.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Zone I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.93 [4.26, 9.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Zone II posterior</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.25 [3.69, 6.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mortality before discharge from primary hospital <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.26, 8.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Zone I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.07, 15.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Zone II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [0.18, 20.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mortality at 30 months of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.30, 2.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Zone I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.16, 2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Zone II posterior</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.26, 8.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Local adverse effects ‐ corneal opacity requiring corneal transplant (unit of analysis: eyes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Zone I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Zone II posterior</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Local adverse effects ‐ lens opacity requiring cataract removal (unit of analysis: eyes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 2.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Zone I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Zone II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Local adverse effects ‐ endophthalmitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Local adverse effects ‐ vitreous haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Recurrence of ROP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.47, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Zone I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.04, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Zone II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.53 [1.01, 6.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Recurrence of ROP (unit of analysis: eyes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.36 [1.22, 23.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Zone I or zone II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.35, 25.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Zone II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.53 [0.98, 58.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anti‐vascular endothelial growth factor therapy versus cryo/laser therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/references#CD009734-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009734-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Anti‐vascular endothelial growth factor therapy plus cryo/laser therapy versus cryo/laser therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Structural outcome ‐ retinal detachment (unit of analysis: eyes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.12, 0.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Local adverse effects ‐ perioperative retinal haemorrhages (unit of analysis: eyes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.24, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Recurrence of ROP by 55 weeks' postmenstrual age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.12, 0.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Anti‐vascular endothelial growth factor therapy plus cryo/laser therapy versus cryo/laser therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009734.pub3/references#CD009734-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009734.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD009734-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD009734-note-0011">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009734-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD009734-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD009734-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009734-note-0004">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009734\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009734\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009734\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009734\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009734\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009734\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009734\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009734\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009734\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009734\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009734\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009734\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009734\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009734\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009734\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009734\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009734\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009734\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7a2tKMcJ&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009734.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009734.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009734.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009734.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009734.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715663968"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009734.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715663972"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009734.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d8c993f809371',t:'MTc0MDcxNTY2NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 